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ABSTRACT 
The total syntheses of BocAL(Z)QAMC (i) and BocAL(Boc)Q(Trt)AMC (ii)  have been 
accomplished. Synthesis of compound (i) was achieved by initially coupling the amino acid 
adjacent to the fluorophore, AMC, using selenocarboxylate / azide amidation coupling 
conditions, followed by the dipeptide coupling on to the third amino acid in the sequence Q 
using the coupling reagent HATU, under optimised conditions.1 Synthesis of compound (ii) 
was achieved using automated peptide synthesis of the protected tripeptide sequence and 
the final coupling to the fluorophore; AMC was achieved using HATU, under optimised 
conditions.  
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Figure i – Structure of BocAL(Z)QAMC 
 
1X. Wu and L. Hu. (2007). Efficient Amidation from Carboxylic Acids and Azides via Selenocarboxylates: Application to 
the Coupling of Amino Acids and Peptides with Azides. Journal of Organic Chemistry.72, p765-774. 
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Figure ii - Structure of BocAL(Boc)Q(Trt)AMC 
The integrity of compound (i) and its fragment Q-AMC was found to be compromised 
during purification steps and storage, by spontaneous decomposition resulting in the 
premature, non-enzyme assisted cleavage of the fluorophore, AMC. This decomposition 
was minimised by the addition of the bulky trityl protecting group, therefore compound (ii) 
was used for biochemical testing. 
Successful deprotection of compound (ii) was accomplished prior to the enzymatic assay, 
with the target enzyme 3Cpro. Importantly, the proof of concept has been gained through 
evidence of enzyme assisted breakdown of the detection probe by fluorescence 
measurements. Also the deprotected version of compound (ii) was found to show 
selectivity towards the target enzyme FMDV 3Cpro over other enzymes potentially also 
present in clinical samples. These enzymes include chymotrypsin, thrombin and trypsin in 
FMDV clinical samples and the carefully selected TEV protease due to its reported 
cleavage after amino acid Q in peptide sequences.2 However, problems with the stability of 
the detection probe after deprotection were still apparent, resulting in a very short shelf-life 
of the probe. Further work is to be done in the stability of the probe but this project has 
proved 3Cpro recognises and processes shorter peptide fragments, previously reported not 
to be the case.ready to print your final version.print your final version. 
 
2J. R. Birtley, S. R. Knox, A. M. Jaulent, P. Brick, R. J. Leatherbarrow, and S. Curry. (2004). Crystal Structure of Foot-
and-Mouth Disease Virus 3C Protease New insights into catalytic mechanism and cleavage specificity.The Journal of 
Biological Chemistry.280 (12), p11520-11527. 
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1. INTRODUCTION 
This introductory chapter covers important points highlighting the 
research over the last few decades, in the area of foot and mouth 
disease (FMD) and the reasons why FMD is a major economic problem 
and the imperative need of the rapid detection of this specific viral 
pathogen. Based on this choosing a target enzyme is considered 
followed by selecting a suitable substrate sequence and the fluorophore 
needed to design and synthesise a suitable fluorogenic substrate.1 
1.1.  TARGET DISEASE 
1.1.1.  Foot and mouth disease 
FMD is highly infectious and contagious; it is responsible for global 
economic devastation and is classed as a trans-boundary disease. 
The causative agent is a pathogen made fast-evolving via high 
mutation rates, specifically the foot and mouth disease virus (FMDV).2 
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Figure 1 – A visualisation of the 3D X-ray crystallographic structure 
of FMDV at 2.9Å resolution.3 
FMDV has a single stranded, positive sense, RNA genome (8,400 
nucleotides in length). It is classed as an Apthovirus and belongs to 
the Picornaviridae family. The genome is found within viral particles in 
protein shells made up of 60 copies of 4 different viral proteins (VPs) 
VP1, VP2, VP3, VP4. These four are a product of proteolytic 
processing of the polypeptide encoded by an open reading frame 
(ORF) of 7,000 nucleotides within the viral RNA. The polypeptide also 
includes two separate proteases: Leader (Lpro) and 3C protease 
(3Cpro).  
 
Replication of the virus occurs in the cytoplasm and is prone to errors 
giving rise to antigenic variance. FMDV exists in seven different 
serotypes, these are: O, A, C, South African Territories (SAT) 1, 2, 3 
and Asia 1. Immunity conferred from an infection or vaccination does 
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not confer immunity for subsequent infections of another serotype or 
indeed the same serotype after a long period of time as the virus 
consensus sequence changes at about 0.5 – 1% of its genome per 
year.4 This equates to 1-2 nucleotide changes per week. Therefore in 
an outbreak there is a possibility the spread of virus between farms 
may be different. However, in terms of classifying subtypes, a 
nucleotide difference of 15% in VP1 region is needed to define a new 
sub-type.5 
 
 
Figure 2 - The FMDV genome, ORF is depicted in the boxed area. 
Labelled are the structural and non structural proteins.6 
 
1.1.2.  Clinical Symptoms 
The appearance and severity of symptoms can vary between different 
animal species. FMD affects in cloven-hoofed animals, including 
cattle, sheep, goats and pigs and a further 70 wildlife species, 
however, some species show no symptoms during infection.7 Other 
factors influencing symptoms include the age of the animal and the 
strain of the infective pathogen, the host’s immunity and the breed of 
the animal. The zoonotic risk is reported to be negligible.8 
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Typical clinical symptoms seen in cattle are blisters, vesicular lesions 
in the mouth area and feet hence the name foot and mouth disease. 
Lameness after blisters burst, fever and reduction in lactation resulting 
in a major loss in milk productivity. Pigs and sheep develop less 
obvious blistering on other parts of their bodies, but sudden lameness 
is the key clinical symptom to raise alarm and in the UK this would 
involve notifying the Animal and Plant Health Agency vets and failure 
to do so immediately, is considered a criminal offence.9 The clinical 
symptoms seen in pigs are indistinguishable from other vesicular 
diseases (swine vesicular disease, vesicular exanthema and vesicular 
stomatitis) therefore people working with pigs presenting symptoms 
are instructed to treat as FMD until a lab-based diagnosis is sought. 
As not all FMD susceptible animals present such obvious clinical 
symptoms, this further complicates the challenge of controlling an 
outbreak in a population.10  Disease signs appear within 2/3 days after 
exposure and can last over a week without further complications.11 
 
The case - fatality remains low overall, adult animals have a low 
mortality rate of <5%, younger animalshave higher mortality rate of 
>20% from complications of the disease such as myocarditis. With 
high morbidity there is a significant effect on the economy especially 
in FMD endemic areas that trade under strict guidelines of terrestrial 
code of the World Organisation of Animal Health with a further 
negative impact on the wider economy and a halt in the development 
of these nations.12,13 
1.1.3.  Current diagnostic techniques employed 
FMDV is an extremely contagious viral pathogen and an outbreak 
caused by this virus depending on its scale and location can cause 
economic devastation, food insecurity, poverty and restrict food trade. 
Therefore, strategies to control, manage and possibly prevent the 
spread of infection via early detection are a requirement. The world 
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organisation of animal health have published a manual of diagnostic 
tests and vaccines that defines FMDV diagnosis tests and states 
diagnosis can be achieved via virus isolation, detecting nucleic acid, 
viral antigen, virus specific or viral non structural protein (NSP) 
antibodies irrespective of vaccination status of the animal. A number 
of lab-based diagnostic techniques are listed that can be used to 
detect viral pathogens and give a clinical diagnosis; over the years a 
range of these molecular biological tests have been modified to 
specifically detect FMDV; complement fixation test (CFT), virus 
neutralisation (VN), enzyme linked immunosorbent assay (ELISA) and 
polymerase chain reaction (PCR).14 
Over the last decade, there has been a rise in research publications 
reporting efforts directed in the area of developing, evaluating and 
validating suitable portable molecular diagnostic platforms (pen-side 
diagnostics) to address the critical time gap of suspicion of infection 
and gaining a rapid, accurate clinical diagnosis. The delay in 
diagnosis is caused by the need of the infected sample being 
transported to a high containment laboratory with certification to work 
with FMDVand analysed by skilled personnel using specialist 
equipment. Other limitations for consideration are; the need of the 
sample originating from a specific source to comply with the 
diagnostic technique – epithelial, blood and sputum, and the expenses 
involved in portable systems and the stability of reagents.15 
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1.1.3.1.  Laboratory based biological FMDV diagnostic    
techniques and how they work. 
Complement fixation test (CFT) 
The principle of the CFT is based on an antibody – antigen reaction, 
these are of IgG or IgM classes. The complement attaches to a fixed 
antibody-antigen complex, a positive result is confirmed through 
absence of hemolysis. However, if serum without the antibody is being 
tested, no complement fixation reaction occurs as no complex is formed 
between the antigen and the antibody, the unused complement causes 
hemolysis which gives indication of a negative result. CFT is based on 
a highly specific interaction and therefore used as a diagnostic tool. 
 
 
 
 
 
 
 
 
Figure 3 - Complement Fixation Test16 
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Virus neutralisation (VN) 
 
The principle of VN is also based on an antibody and antigen 
interaction, this technique neutralises the biological effects of the virus 
through antibodies making it inactive if present in the sample being 
tested, leaving the virus susceptible cell uninfected, the cells are 
analysed after 2 – 3 days, investigation is done using a microscope or 
looking for evidence of viral cytopathic effect. 
 
Figure 4 – The Virus Neutralisation Test17 
 
Polymerase chain reaction (PCR)  
 
PCR is a DNA amplification process, through steps of heating and 
cooling to make copies of specific regions of DNA. First the sample is 
heated to 94°C, causing denaturation into single strands. At a cooler 
temperature of 68°C primers are annealed onto complementary 
matches on the target DNA sequence. The Taq polymerase present 
binds to the primed sequences and extends the second strand, 
completing the first cycle. In subsequent cycles, denaturing, priming, 
annealing and extending are all repeated to gain more DNA copies. 
After 30 cycles, a billion copies of DNA can be produced from the 
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single starting molecule. PCR technology is always undergoing 
improvements and now RNA can also be used efficiently. The RNA is 
first transcribed to DNA using reverse transcriptase, allowing studies 
to be carried out on RNA viruses and cellular RNA, even in small 
quantities.  
 
 
Enzyme linked immunosorbent assay (ELISA) 
 
There are a number of ELISA procedures adapted to detect and 
quantify antibody or antigens in a sample; Direct ELISA, Indirect 
ELISA and Sandwich ELISA. 
 
The setup of direct ELISA involves antigen immobilisation onto the 
wells of a micro titre plate. The antigen is detected by an enzyme-
linked antibody that binds to it and is retained. Detection of the 
retained enzyme is indicative of the presence of the antigen and is 
observed via a colour change, fluorescence measurements or 
chemiluminscence.  
 
Indirect ELISA, where an antigen is adsorbed and immobilised onto 
the wells of a micro titre plate, the excess is then rinsed off. The 
serum suspected of containing antibodies is then added, the enzyme 
linked antibody is capable of attaching itself to the constant region of 
the antibody, once attached and in presence of the colourless 
substrate added, a colour change is observed.   
 
Sandwich ELISA, is used to detect antigen; the procedure involves 
immobilisation of the antibody in the micro titre plate wells. The test 
sample is then added with the suspected antigen, time allowed for 
incubation to enable antibody-antigen reaction to occur. The excess is 
rinsed out and a second enzyme-conjugate antibody is added, this 
secondary antibody is expected to bind onto a different epitope of the 
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antigen and any excess unbound antibody is rinsed off. The 
colourless substrate solution is added and a colour change is 
indicative of antigen presence.  
 
CFT was the chosen method for diagnosis in the seventies and is still 
used in many developing countries where there is a shortage of 
expensive modern, equipment. This technique requires a large viral 
concentration to give a positive result. However, result interpretation 
was also reported to be affected by pro- and anti-complementary 
activities in the test sample, making the test less reliable due to this 
reduced specificity. The VN technique in combination with cell 
culturing techniques was found to be 100 times more specific than 
CFT, however, cell culture is a time consuming and expensive step to 
be carried out by skilled staff within suitable bio-containment facilities. 
The results from VN/CFT were found to be prone to variability and 
therefore not as widely used. In the late seventies, Crowther et al. first 
reported indirect ELISA as a technique used to screen for antibodies 
against FMDV. ELISA was modified over the years and applied for 
viral detection, typing and serotype definition. ELISA was found to be 
superior to CFT and VN as it gave reliable, accurate, reproducible 
results in 3-4 hours of reaching a laboratory. However, using ELISA to 
elucidate the serotype of the virus requires a further four days; this 
delay is the reason for the further development of PCR as a diagnostic 
tool for FMDV. Reverse transcription PCR (RT-PCR) has the added 
advantage of requiring the virus to be rendered inactive by RNA 
extraction. Arguably, the current gold standard is said to be PCR as 
the diagnostic tool of infectious agents, the advantages of this 
technique of greater sensitivity, improved specificity and reduced 
contamination risk, however, DNA/RNA amplification delays gaining a 
final result and is costly, therefore a need for cost effective, rapid, 
accurate diagnostic tests is still apparent.18 
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1.1.3.2.  Pen-side diagnostics 
To date three main pen-side diagnostic technologies are reported: 
i) nucleic acid detection using RT-PCR  
ii) antigen detection using different formatted lateral flow devices 
(LFD) 
iii) LFD detection after isothermal amplification using primers of 
certain regions of the FMDV genome.   
PCR techniques are considered first choice by many laboratories,19as 
it can detect viral genome or fragments of the virus in samples that 
aren’t able to grow in tissue culture, whereas ELISA and virus 
neutralisation techniques require a sample to contain intact antigens 
or the live virus to test on. PCR is therefore considered a powerful and 
sensitive technique and potentially a useful detection system to have 
on the field, hence the development of a portable PCR system for 
FMDV detectionwas an exciting concept.20,21,22 However, field testing 
made apparent the limitations of the system as it requires a precision 
thermo-cycling step that is carried out using expensive, fragile 
instrumentation that required a vigorous decontamination protocol of 
the instrument to be followed after each site use.23 In order to reduce 
costs associated with the necessary cycling at different reaction 
temperatures for the portable PCR system, isothermal amplification 
strategies were explored in viral diagnostics.24 In 2000 Notomiet al. 
developed a molecular technique loop mediated isothermal 
amplification (LAMP) widely used to detect viruses when in 
combination with reverse transcriptase. Notomi et al. proved DNA/ 
RNA can be amplified rapidly by heating under a constant 
temperature with a set of four specific primers, also reported is that 
loop primers can help the amplification process.25 
 
Recently, other simpler, cheaper, rapid pen-side diagnostics have 
been developed in the form of LFDs. Although the lateral flow 
immunoassay diagnostic platform was first reported in the 1980s, 
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FMD LFDs are a more recent addition to a diverse range developed 
and marketed over almost 40 years, a few examples are in table 1.26 
 
Application 
area 
Analyte Label Sample 
type 
Detection 
limit 
Time to 
detection 
Clinical 
analysis 
Alpha 
fetoproteins 
Quantum 
dots 
Serum 1 ng /mL 10 min 
Pathogens  Escherichia 
coli mRNA 
Liposome Drinking 
water 
5 fmol 15-20min 
Metal ions Mercury  Gold nano-
particles 
Water 6 nM 5 min 
Pharmac-
euticals 
Sulfonamides Gold nano-
particles 
Eggs and 
Chicken 
muscles 
10 ng/mL 15 min 
Table 1- adapted from a literature review of lateral flow assays, 
showing a few examples of LFDs developed over the years.27 
There are four main components in an LFD: 
i) Sample application pad – where sample is added. 
ii) Conjugate pad – holding labelled tags combined with 
recognition elements. 
iii) Nitrocellulose membrane – containing control and test line, 
this membrane has high affinity for biomolecules. 
iv) Adsorbent pad – marks end of the strip, soaks up sample to 
prevent back or over flow. 
 
FMD LFDs that have been reported over the last decade: 
 
In 2009, Ferris et al. reported the development of LFD using a 
monoclonal antibody (mAb) mAb1F10 as a tracer and conjugated to 
gold nanoparticles, performance of the LFD was tested against over 
1300 samples as vesicular epithelial suspensions. The group also 
further validated the device by comparing to reference method of 
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antigen ELISA (Ag-ELISA), with diagnostic sensitivity and specificity 
for LFD 84% and 99% respectively and for ELISA 85% and 99.9%. 
The time of detection was between 1 – 10 minutes after sample 
addition. No false positives were seen with clinically indistinguishable 
SVD and VS. However, the main limitation of the 1F10 device is it has 
weaker reactions with serotype SAT-2 resulting in false negatives.28 In 
2010, the group reported the development of a new SAT-2 specific 
LFD, using Mab2H6, evaluated against over 300 samples as vesicular 
epithelial suspensions.29  The validation studies showed the 2H6 
device had higher diagnostic sensitivity at 88% than the reference Ag-
ELISA at 79% and similarly impressive diagnostic specificity at 99% 
as compared to 100% by ELISA. The group recommend using the two 
devices in tandem to screen samples of all known serotypes.  
 
In 2009, Oem et al. reported a similar device using mAb 7017, 
however, LFD didn’t react with all serotypes, only four of the seven 
serotypes were detected, types O, A, Asia 1 and C. The LFD was 
tested against 704 epithelial samples. The diagnostic sensitivity for 
the LFD was at 87.3% compared to Ag-ELISA at 87.7%. The 
diagnostic specificity for the LFD was at 98.8% compared to Ag-
ELISA at 100%. The group reported the usefulness of this assay in 
regions prevalent in the detectable serotypes.30 
 
In 2010, Cai et al. reported an immuochromatographic strip to detect 
FMDV performance evaluated on 296 serum samples and validation 
studies against ELISA, the group reported the strip showed high 
sensitivity and specificity.31 
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Figure 5- Schematic diagram of an immunochromatographic test strip 
for the detection of antibodies against foot and mouth disease virus 
serotype O, using gold labelled antigen, test line is bio-marked with 
staphylococcal protein A and the control line with swine anti-FMDV 
antibody IgG.  Sample was reported to be diluted 100 fold with saline 
solution before adding to sample pad, the sample moves towards the 
absorbent pad via capillary action, a positive sample containing target 
antibodies will bind to the colloidal gold antigen – forming an antigen -
antibody complex highlighted by a red band. The time of detection 
was 5 minutes after sample addition.32 
The LFDs are rapid, deployable detection platforms, however, 
antibody / antigen based LFDs offer equivalent or less diagnostic 
sensitivity to Ag-ELISA of certain serotypes, and can only be applied 
to the acute phase of FMD where samples collected contain high 
amounts of viral particles from vesicular or epithelial samples. These 
application requirements render the device useless in the incubation 
period and in absence of obvious clinical signs whereas isothermal 
based assays allow the evaluation of samples from various sample 
types: epithelial suspensions, serum and oesophageal-pharyngeal 
fluids.33 
 
More recent publications report developments of portable hardware 
and protocols for conducting LAMP assays on the field. In 2014, 
Waters et al. reported the developments of a modification of an FMDV 
– specific RT LAMP assay to allow detection of dual labelled LAMP 
products with an LFD.34 The group report a 104 fold higher analytical 
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sensitivity than the current antigen – lateral flow device (Ag-LFD) 
(SVANODIP FMDV-Ag, Svanova) used on sites. Furthermore other 
advantages are highlighted when comparing to the ‘gold standard’ 
portable PCR system, the RT LAMP assay relies on robust isothermal 
chemistries and therefore doesn’t need time consuming, specialist 
equipment to support prior nucleic acid extraction. Interestingly, after 
optimisation the RT-LAMP LFD assay was able to detect different 
serotypes and also able to detect low levels of FMDV in air samples 
further supporting the group’s claim of higher analytical sensitivity. 
FMDV presence in air sample detection is a very valuable 
development as this form of indirect transmission is a reported 
problem in FMD outbreaks making it a trans-boundary disease 
therefore this assay in a deployable kit would be a valuable tool for 
early diagnosis and prevention of a mass viral outbreak. 
 
A further complication with pen-side diagnostic kits is the need to 
maintain the integrity of the reagents such as enzymes being utilised, 
through temperature controlled storage and transportation needed for 
stockpiling test kits as a precautionary measure or deployment to 
suspect cases. All techniques mentioned thus far have been validated 
by ‘wet’ reagents, to address this gap methods have been developed 
to lyophilise reagents making them stable to less optimal/ harsher 
conditions as seen in many areas affected by FMD. In 2015, Howson 
et al. have reported the validity of the use of lyophilised reagents in 
field settings of East Africa (FMD endemic location) on RT-LAMP and 
RT- PCR assays, the group have reported no adverse affect on the 
performance of the assays.35 
 
1.1.3.3.  Other strategies to improve rates of diagnosis 
Cost effective method to submit FMDV sample; a study has been 
reported by Kassimi et al. on a cost effective protocol for sample 
submission in conjunction with LFD used for rapid immunodetection, 
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utilising a positive test strip after rendering the virus inactive by 
soaking the test strip in 0.2% citric acid, the study was done to reduce 
the cost of submission thereby increasing the number of samples 
submitted from suspected animals, especially in endemic areas.36 
 
The imminent need for a cheap, rapid, sensitive test for FMDV is 
apparent for the 3Cpro enzyme and capable of detecting all serotypes 
known. However, elucidation of the serotype would have to be lab 
assisted but this can be done with samples that generate a positive 
fluorescence response, reducing the number of suspected samples 
being sent to labs and the costs associated with them. We envisage 
the use of a marker spray that can produce a fluorescence signal 
when in presence of the FMDV, with the use of a portable fluorimeter, 
minimal user intervention and easy to follow protocol that can be 
followed by non-specialist personnel. Preliminary studies have been 
carried out on 3Cpro and further optimisation is needed to apply to 
actual clinical samples from different sources such as blood, serum, 
fluids as the presence of other components in the sample may have 
an effect on the performance of the assay developed.  Research 
efforts have goneinto synthesising a suitable peptide fluorophore 
conjugate and its biological evaluation in the presence of 3Cpro. 
 
1.1.4.  Global distribution and economic impact 
Although the mortality rate of FMD remains low, an outbreak affects a 
large number of animals having a major global impact on livestock 
productivity, livestock products, milk production and on import/export 
with other countries thereby adversely affecting the economy of the 
host country.It is reported that three quarters of the world’s population 
collectively reside in FMD endemic countries; therefore FMD remains 
a global problem.37 
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Figure 6 - The map indicates locations with FMD outbreaks and their 
resolution status, representing data from 2020.38 
The UK is listed by the OIE as a Member of Countries as FMD free 
where vaccination is not practised.39 The UK has suffered two 
outbreaks in the last 20 years, a major outbreak in 2001 and a minor 
outbreak in 2007 due to the preparedness of the country after 2001’s 
outbreak. The 2001 widespread outbreak was caused by the Type O, 
PanAsia strain of FMDV and cases were also reported to be found in 
Northern Ireland, Ireland, Netherlands and France. The overall cost of 
this outbreak was reported to be around £8 billion, £3 billion losses to 
the public sector and £5 billion to the private sector (national audit 
office). The country faced mass culling of infected/suspected animals 
in order to prevent the spread of infection; 6.24 million in total were 
lost. An increase in suicide in farmers was reported around the 
epidemic. 120,300 farms were affected and depopulated. UK regained 
its FMD free status in 2002 allowing reopening of export; however, 
normalised trading was achieved after 18 months of eradication. The 
agricultural and food chain industries were compensated by the 
government, but other sectors were also affected, this extension 
thereby affects the whole British economy this includes the tourism 
industry that was reported to be hard hit by the outbreak, with direct 
losses reported from rural and overseas tourism. 90% of positive 
samples from cattle and pigs were detected via ELISA using vesicular 
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epithelial samples. Less vesicular lesions were observed in sheep and 
therefore this technique is not as suitable or successful for detecting 
FMDV in sheep.40,41,42,43 
 
The 2007 outbreak was caused by virus strain British Field Strain 
1860, serotype O, subtype 1, isolated in 1967 from a surprise leak 
from the Pirbright site made up of the Institute of Animal Health and 
Merial Animal Health Limited, both laboratories were working with this 
strain at the time, 4.4km distance away from the first diagnosed 
case.44 The overall cost associated with this outbreak was reported to 
be £100 million. The FMD spread was more controlled and therefore 
the spread of infection was localised, the number of animals culled 
were 2,160 and the number of farms depopulated were 8, with no 
farmer suicides reported. The duration of the outbreak was 4 months 
and UK regained its FMD free status after 2 months of eradication 
allowing reopening of exports. 
 
 
Figure 7- Major FMDV events between 2007-2014 and the pools of 
serotype in different regions.45 
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The impact of an outbreak varies from country to country and sector to 
sector, however, the economic losses associated with eradication 
areinevitably large. In 2013, Rushton et al, reported a massive 
collective loss of over US$20 billion over the last 15 years due to 
epidemics in countries previously free of disease. The status of a 
country with regard to FMD is of high importance when considering 
trading of livestock products. The presence of FMD in a country such 
as in endemic countries renders its prospects to be low of exporting to 
FMD free countries. However, maintaining a FMD free status is costly 
and at times a struggle to maintain in developing countries. Loss of 
FMD free status results in reduced export revenue, increased supply 
to domestic markets would reduce meat prices causing a massive 
loss to the meat industry over a long period of time. Moreover 
countries sufferingendemics are impacted via on-going losses both 
direct and indirect losses as described in figure 8. 
 
Figure 8 - The direct and indirect losses and problems contributing to 
the overall impact of FMDV.46 
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1.1.5.  Vaccination 
Vaccination is a common method of control in infectious diseases and 
has in the past reported to support eradication invetinary areas. 
However, conferring immunity against FMDV to prevent or reduce 
clinical disease is complicated, as the virus undergoes error prone 
replication giving rise to seven different serotypes, these serotypes 
have further subtypes. Serotype specific vaccines are available, these 
vaccines usually only provide resistance for the specified serotype/s. 
Distribution of the serotypes isn’t uniform across endemic regions, 
however the cluster of serotypes present in each region is known 
through continuous diagnosis as shown in Table 2 - Distribution of 
serotypes in some regions suffering endemics. An infection caused by 
serotype C hasn’t been reported since 2004 and is therefore now 
thought to be extinct.47,48 
 
Region Serotypes 
Africa O, A, C, SAT-1, SAT-2 and SAT-3 
Asia O, A, C, and Asia-1 
S. America O, A, and C 
Table 2 - Distribution of serotypes in some regions suffering endemics. 
FMD vaccination policies vary from country to country, depending on 
their policy makers local epidemiological situation and export markets:  
 
- Regions facing FMD endemic situations such as: Africa, Asia 
and South America all practice preventive vaccination.  
Countries within these areas are reported to be controlling 
disease via mass immunisation using a trivalent vaccine 
containing inactivated antigens of O, A and Asia-1 serotypes 
prevalent in India.49 
- Europe, North America and Australia are free of FMD without 
vaccination.  
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The EU has banned the use of routine vaccinations since 1992, 
therefore the UK in an epidemic situation (2001) followed a 
strict stamping out policy causing pre-emptive culling of 
animals on infected farms and their dangerous contacts. This 
method of control caused a public outcry resulting in part toa 
change of policy to use vaccination as a primary method of 
control spread of infection. The EU regulation now states 
emergency vaccination (protective vaccination to survive) can 
be considered in conjunction with culling to control spread of 
infection, depending on availability and efficacy of vaccine as 
success in stamping out policy is entirely dependent on early 
diagnosis.50 
 
Use of preventive vaccination is predominantly used in endemic 
countries, unlike countries usually free of FMD that face sporadic 
outbreaks who decideagainst the use of preventive vaccination and 
use emergency vaccination as a last resort because of reasons 
reported below: 
 
i) In order to develop large amounts of vaccine, the traditional 
method would involve inactivation of large amounts of the virus 
and cultivation of the virus poses the major risk of virus escape 
from a high containment lab as seen in the UK 2007 outbreak.  
ii) Unable to prevent sub-clinical persistent infection that is equally 
as infectious if transmitted as from an animal in acute phase of 
infection. 
iii) Costs associated with routine vaccination – direct vaccination, 
administration and surveillance of immunity, movement 
restrictions implied on animals after vaccination. Although in 
most cases this control strategy would outweigh income 
generated through trade deals of a country holding a FMD free 
status, benefitting the overall country’s economy. 
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iv) An added complexity to emergency vaccine administration is the 
need for subsequent differentiation of groups of animals that are 
vaccinated from the ones that are infected - recovering from an 
infection or suffering an acquired sub-clinical persistent 
infection. This information cannot be currently achieved using 
regular diagnostics, however, priority in research is now to 
develop vaccines alongside specifically designed diagnostics 
able to differentiate between infected and vaccinated animals 
(DIVA).  
The DIVA strategy allows vaccination producing an antibody response 
that is different to the antibody response produced by FMDV thereby 
holding the advantage of serological surveillance for the presence of 
infection, alongside a diagnostic method optimised to detect carefully 
selected epitopes and antigenic determinants.51 
 
Current vaccines are binary ethyleneimine inactivated whole virus 
antigen, with newer vaccines developed with markers in the form of 
deletions of NSPs through biological intervention resulting in genomic 
mutations of the FMDV. Conventional FMD vaccines provide 
protection to different extents and come with a few limitations: 
i) Working with large amounts of whole antigen can result in viral 
escape from high containment laboratory. 
ii) Vaccines not all compatible with DIVA strategy and therefore 
not appealing to countries that favour emergency vaccination 
use over preventive vaccination. 
iii) Short term protection period, requires constant booster 
vaccinations. 
iv) Needs constant updating due to evolving FMDV giving rise to 
subtypes.  
v) Specialist storage required for formulated vaccines. 
vi) Short shelf life. 
vii) Cultivation of some serotypes/ subtypes can be difficult. 
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viii)Incomplete inactivation – very rare for inactivation to occur 
today as methods to inactivate are now more understood. 
 
Other types of vaccines have been developed over the years, 
designed to circumvent problems highlighted above. One type of 
vaccine developed is with the FMDV rendered harmless to susceptible 
animals, by producing FMDV with deletions of essential 
proteins/proteases needed for virulence. An example of this is 
Leaderless FMDV production, which lacks the Lpro enzyme and when 
tested as a vaccination equivalent protection was described as 
observed using the wild type antigen. Uddowala et al. further 
developed the Leaderless FMDV by adding mutations in 3D and 3B 
giving desired DIVA characteristics and when tested as a vaccine - 
100% protection was reported. A possible limitation for this type of 
vaccine for the FMDV is that it may revert back to its virulent form. 
Moreover, peptide vaccines were developed by synthesising 
polypeptide chains of the most antigenic region of the viral genome – 
VP1, more specifically the G-H loop that is the most antigenic site, 
however, the protection was reported at a low 40%. More recently, 
synthesis of polypeptides to mimic immunogenic epitopes of VP1, 3A 
and 3Dpol gave a more promising protection percentage of 60%. More 
recently a DNA vaccine was developed containing fragments of the 
antigen - P1 capsid region and NSPs 2A, 3C and 3D, incurred 75% 
protection as a vaccine with the added advantage of assembly in 
lower containment laboratories and with a stable shelf life.52 
 
This thesis details the development of a diagnostic technique with 
potential to have DIVA compliance by targeting an enzyme self-
cleaved from the viral genome – 3Cpro. As mentioned above the 
development of the Leaderless vaccine if modified to delete the 3Cpro 
in conjunction with a 3Cpro marker spray, a positive response would 
thereby mark the presence of 3Cpro indicative of infection and the 
absence would be indicative of vaccination.  
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1.1.6.  Transmission 
FMD is a highly contagious disease and understanding transmission 
pathways is helpful information when containing the spread of 
infection. Viral particles have been detected in many bodily secretions 
and excretions of an infected animal before the onset of anyclinical 
signs; these bodily fluids include blood, saliva, serum, oesophageal 
and pharyngeal fluids and also in exhaled air. With transition into the 
acute clinical phase of infectionand formation of lesions, viral particles 
are also detected in shedding from ruptured lesions as well as all the 
secretions mentioned before. 
 
Transmission can occur in two ways; direct contact or indirect contact 
in countries with endemic FMD status. On the other hand epidemics in 
previously FMD free status can be totally unpredictable and can be 
caused by air-bourne spread of viral particles as circumstantial 
evidence indicates from an outbreak seen in 1981 in the Isle of Wight, 
thought to have originated from Brittany in the North of France. The 
virus is reported to be able to travel significant distances depending 
on the wind strength/direction, humidity and climate of area further 
complicating the spread of infection in an outbreak. FMDV is reported 
to survive between days to months in surroundings, the virus is also 
found in animal products such as meat therefore strict guidelines are 
followed for heating pig swill, as many outbreaks in the past have 
been linked to FMDV infected products being fed to pigs resulting in 
an outbreak.53 
 
The role of carriers in transmission isn’t completely understood. More 
recently Hayer et al.54 reported the time taken for full viral clearance 
from Indian cattle to be 13 months, lower than previous reports of 
carrier state to last between 2-3 years. Another group led by 
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Bronsvoort have noted younger animals are more likely to be carriers 
after an outbreak due to sero-conversion.55 
 
1.2.  THE TARGET VIRUS 
1.2.1.  Picornavirus 
The Picornavirus belongs to the family Picornaviridae, which belongs 
to the order Picornavirales that currently consists of 94 species 
grouped in to 40 genera (as of March 2018).56 Characteristic features 
of picornaviruses are; typically small ~18-30nm with single stranded 
positive sense RNA, RNA molecules range between 7.2 – 8.5 
kilobase (kb), they lack a lipid membrane around their genome 
rendering it resistant to solvents: ether, chloroform and alcohol, but 
readily inactivated using phenol, formaldehyde or ionising radiation.57 
These viruses are responsible for a range of human and animal 
diseases that present themselves as sub-clinical infections with 
varying degrees of intensity from a mild illness to severe illnesses of 
the heart and liver, a few members of the family Picornaviridae are 
listed in table 3.  
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Table 3 - Other diseases caused by picornaviruses.58 
 
 
 
 
 
 
 
 
Genera that infect animals Species and disease 
Apthovirus FMDV – disease in cloven hoofed 
animals 
Cardiovirus Theiler's murine encephalomyelitis 
virus - disease in rodents 
Teschovirus Teschovirus A– disease in pigs  
Genera that infect humans Species and disease 
Enterovirus 
 
Polio virus – disease of alimentary 
canal 
Rhinovirus Common cold virus – disease of 
nasopharyngeal region 
Hepatovirus Human hepatitis virus A – disease of 
the liver tissue.   
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1.2.2.  FMDV genome and structure 
FMDV is a small non-enveloped virus, each viral particle contains 
capsids that are protein shells encasing 8.4kb of viral genome that is 
attached via a covalent linkage at the 5’ end to the a small viral protein 
linked to the genome (VPg)  and polyadenylated on the other 3’ end.59 
Subsequent to viral cell entry, the viral genome undergoes three main 
steps; (i) rapid translation into a long 2,300 amino acid chain that is 
processed by twovirally encoded proteases, (ii) cleavage of proteins 
and (iii) replication of FMDV genome by viral polymerase 3D pol. The 
replication of FMDV is thought to be confined to the cytoplasm with an 
efflux of certain nuclear host factors.  
 
 
Figure 9 - A diagram representing the FMDV genome, the mature 
viral proteins are labelled in boxes. Protein processing key: the 
arrows indicate the cleavages done by 3Cpro, the circle indicates the 
junction at which a ribosomal skip mechanism occurs and the square 
indicates the position for auto-catalytic cleavage by Lpro, the diamond 
represents position the capsid proteins undergo maturation 
cleavage.60 
 
The FMDV genome like all picornaviruses is made up of the long 
single ORF flanked by 5’ and 3’ non coding regions (NCR). The 5’ 
NCR holds sites – 3 to 4 pseudoknots, cis-acting replication element 
and IRES type 2 that have important roles in cap-independent 
translation initiation of viral proteins and genome replication. The 3’ 
NCR end is thought to also hold replication elements needed for 
efficient replication, deletion of either 5’ or 3’ sites is reported to cause 
inhibition to translation in lab based studies.61 The ORF encodes a 
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polypeptide cleaved by the virally encoded proteases to give mature 
viral protein products these include eight non structural proteins 2B, 
2C, 3A, 3B, 3Dpol, Lpro, 2A, 3Cpro and four structural proteins VP1-4.  
 
These structural proteins form an icosahedral capsid with pseudo T=3 
symmetry to protect the viral RNA genome, it is composed of 60 
copies of each VP.  The symmetry is described as pseudo as each VP 
doesn’t occupy the same space. The VPs are organised into 12 
pentamers to make a whole capsid, each pentamer is made up of five 
protomers and each protomer is made up of all four structural proteins 
VP1-4. With VP1-3 making up the outer surface and the VP-4 protein 
assembled internally. A highly conserved tripeptide of (Arg-Gly-Asp, 
RGD) motif externally expressed on the surface of each capsid is an 
important feature for virus neutralisation anda primary contact for 
initiating viral infection by interacting with integrin receptors on the cell 
membrane.62 
 
Figure 10 - Biological assembly of FMD viral particle exhibiting 
icosahedral global symmetry.63 
The method of viral entry into host cells is via receptor-mediated 
endocytosis. FMDV receptors reported to mediate FMDV infection 
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include the integrin cell surface receptors - αvβ1, αvβ3, αvβ6 and 
αvβ8 or using the heparan sulfate receptor via interaction with the 
RGD motif externally assembled in the FMDV capsid. The endosomic 
area of the host cell is acidic and FMDV capsids are unstable below 
pH 6.5, causing dissociation into pentamers and release of viral RNA 
genome. However, the translocation of the RNA genome from the 
endosome to the cytoplasm remains unclear, as the movement 
involves the capsid withstanding changes in pH and passing through a 
lipid bi-layer of the endosomal membrane to reach the cytoplasm 
before reassembly.64 
 
1.2.3.  Virally encoded proteases as a target marker 
The Le Gresley group have recently developed a rapid detection 
system as an alternative to the PCR based methodology for 
Staphylococcus aureus (SA) bacteria utilising the probe called LGX - 
(BocNH-Val-Pro-Arg)2–Rhodamine.65 The system is originally inspired 
by the commercially available probe BocNH-Val–Pro–Arg–7–amido–
4–methyl coumarin,66 used for the detection of SA bacteria through an 
enzymatic approach as illustrated in figure 11. 
i) 
 
 
ii) 
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Figure 11 - (i) Pictorial representation of the concept being tested (ii) 
Structural representation of methyl coumarin dye system. 
Taking advantage of the proof of concept gained through the LGX 
probe on SA bacteria, the method can be further developed to target 
any microorganism that are known to produce an exo-enzyme with a 
natural substrate that mimics a synthetic peptide sequence that can 
be coupled on to a suitable fluorophore like 7-amino-4-methyl-
coumarin (AMC) or a suitable chromophore like rhodamine 110 (R-
110). FMDV is a suitable target for this tested approach, as this 
picornavirus replication is reported to be reliant on externally 
expressed virally encoded proteases. The picornavirus genome is 
reported to be translated into a polypeptide chain which is processed 
by cleavage by virally encoded proteases; Lpro, 3Cpro and 2A, all of 
which have the potential of being possible targets. 
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1.2.3.1.  Leader protease, Lpro. 
FMDV Lpro is a papain-like cysteine protease, its active site residues 
were identified as Cys-51 and His-148 (fig 12) by inhibition studies 
and site directed mutagenesis. The protease exists in two iso-forms 
Lab and Lb as there are two in frame translation initiation codes for 
the protease, the Lab form has a highly variable extension of 28 
amino acids not seen in the Lb form. Both exhibit indistinguishable 
activities and specificities, they are able to self-cleave from the viral 
polypeptide chain and induce cleavage of the eukaryotic initiation 
factor eIF4GI and II resulting in the inhibition of host cells capped 
protein synthesis. However, this has no effect on the viral protein 
synthesis which is maintained since it is reliant on an internal 
ribosome entry site (IRES) within the 5’-NCR.67 
 
A mutated version of the FMDV virus - Leaderless virus is reported to 
be developed and evaluated as a vaccine, the absence of the Lpro 
renders the virus inactive, however, its use as a vaccine is limited 
because the virus is so weakened that it doesn’t replicate enough to 
cause the host immune system to illicit a protective response. An 
initial response of the host to a viral infection is the secretion of 
interferon type I (IFNI), interferons are proteins that bind to host cells 
and via a signal transduction pathway causing the production of anti-
viral gene products. The replication of FMDV is inhibited by the 
presence of IFNI and this IFN activity is detected when infected with 
the Leaderless FMDV.  Interestingly the IFN activity described isn’t a 
problem when using some BHK cell lines as they are reported to have 
a defect to their responsiveness to IFNs making them compatible with 
the Leaderless virus for cultivation purposes.68 
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Figure 12 - Structure of Lpro and the active site residues are 
highlighted. 70 
1.2.3.1.1.  Activity of Lpro 
Lpro is reported to be responsible for only one cleavage on the viral 
polypeptide chain at its own carboxyl terminus at the L/VP4 junction to 
release itself, as shown in figure 9. Once released the enzyme is 
reported to cleave a large number of host-cell proteins as listed in 
table 4. 
 
Host cell protein Function of protein 
Cyclin B2 Control of cell cycle 
Cyclin A Control of cell cycle 
Gemin5 IRES-binding factor 
P65/ReIA Subunit of nuclear factor 
kappaB 
Ubiquitinated proteins Modulate cellular and immune 
processes 
RANTES expression Inflammation and immune 
response 
eIF4Gi and ii Eukaryotic translation initiation 
factor 
Table 4 -Host-cell proteins cleaved by Lpro 69,70,71,72,73 
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The enzyme is reported to be involved in a large number of reactions; 
the comparison of the amino acid sequences of three of its known 
substrates gives an indication of the unique specificity exhibited by 
Lpro: 
Protein Amino acid sequence 
Viral polypeptide chain KVQRKLK*GAGQSS 
eIF4Gi PSFANLG*RTTLST 
eIF4Gii VPLLNVG*SRRSQP 
Table 5 - Amino acid sequences of Lpro substrates, * marks position 
in the sequence that is cleaved by Lpro.71 
Studies conducted on the sequences in table 5 by a number of groups 
revealed that Lpro recognises and cleaves peptide bonds before or 
after basic residues neighbouring glycine. However, basic residues on 
both sides of the scissile bond have shown an inhibitory effect at a 
micromolar range which led to the development of nanomolar inhibitor 
E64,  an epoxide that is reported to have a range of uses, one of 
which is the ability to inhibit Cathepsin B through inducing oxidative 
stress and apoptosis in filarial parasite.7475 
 
1.2.3.2.  2A oligopeptide sequence 
The catalytic cleavage of the VP1/2A junction is a consequence of 2A 
protease activity, in some picornaviruses: the human rhinovirus and 
the poliovirus. Despite initial theories of similar activity on the FMDV 
genome, further studies of the FMDV 2A protein by Ryan et al. has 
proved no proteolytic activity and its cleavage at 2A/2B junction is 
reported to be caused by the mechanism of ribosomal skip. The short 
2A oligopeptide sequence is reported to modify the activity of the 
ribosome by promoting ester hydrolysis of the peptidyl(2A)-tRNAGly 
causing the release of the polypeptide from the translational complex, 
however, some of the RNA remains attached to the ribosome allowing 
the translation of the non-structural proteins but at reduced levels 
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compared to the structural proteins.76,77 The absence of any protease 
activity with this protein renders it useless for this project, as the 
detection model being applied requires a viral exo-enzyme to be 
produced acting as a marker for its native virus.  
 
1.2.3.3.  3C protease, 3Cpro. 
3Cpro is a chymotrypsin-like cysteine protease, it is 213 amino acids 
long with molecular weight of around 23kDa. The enzymes sequence 
is highly conserved, ~82-85% identical over all known serotypes 
without any cellular equivalents in host cells and it is therefore a 
suitable target for our project. Like the Lpro it also self cleaves from the 
viral polypeptide chain and is vital for further processing of the 
sequence as it recognises and cleaves 10 of the 13 polypeptide 
junctions, it also interacts with a wide range of host proteins involved 
in the host’s immunity (table 6), thereby successfully suppressing 
cellular immune responses. This shows that 3Cpro plays a critical role 
in viral pathogenesis.  
 
3Cpro cleaves a large number of amino acid pairs during primary and 
secondary processing, these include; E/G, E/T, Q/L, Q/G, Q/T and 
Q/M, however, not all such amino acid pairs present in the viral 
polypeptide chain or in the capsid proteins are cleaved by 3Cpro, the 
structural positions play an important role in recognition and cleavage.  
 
Host cell protein Function of protein 
eIF4G, eIF4A1 Eukaryotic translation initiation factors 
H3 Histone 
NEMO NF-kappa-B an essential modulator 
for IFN α/β responses  
Sam68 Sequence-specific RNA binding 
protein that regulates alternative 
splicing 
Table 6- Host-cell proteins cleaved by 3Cpro70,78,79 
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1.2.3.3.1.  Active site of 3Cpro 
Resolution of the atomic structure of 3CproFMDV revealed important 
structural features; the enzyme adopts a chymotrypsin like fold as 
observed in most serine proteases with a conserved catalytic triad 
made up of Ser-His- Asp.  However, the catalytic triad of the FMDV 
3Cpro is comprised ofHis-46, Asp-84 and Cys-163, the residue acting 
as a nucleophile in the active site is cysteine. In recombinant forms of 
the enzyme, the cysteine residue is substituted with an alanine to 
produce the inactive form of the enzyme to facilitate expression, 
purification and crystallisation. 
 
In earlier enzyme structural studies a major difference was spotted in 
the substrate cleft of the FMDV 3Cpro, the -loop overlaying the 
substrate binding cleft found in other picornaviruses was disordered 
and reported to be absent and thought to be the reason to the 
reduced substrate specificity exhibited by FMDV 3Cpro as it is able to 
recognise and process glutamine and glutamate residues positioned 
before the scissile bond, not seen in other picornavirus 3C proteases 
who strongly favour glutamine in this position. However, the β-loop 
presence was later confirmed in 2005 by Curry et al. who produced 
more soluble recombinant forms of 3Cpro single (C95K) and double 
(C95K/C142S) mutant proteases in order to determine the crystal 
structure and its proteolytic specificity. The group ran peptide 
cleavage assays and have reported the need for four residues each 
side of the scissile bond for efficient recognition and cleavage.  
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Figure 13- Atomic structure of 3Cpro and the active site residues are 
highlighted.70 
Moreover, structural analysis reported by Curry et al. was based on 
covalent attached substrates or peptide based inhibitors of the 
enzyme. However, in 2010, Zunszain et al.80 resolved the X-ray 
crystal structure of 3Cpro with bound peptide substrates i) 
APAKQ*LLNFD = P5-1*P1’-5’effectively mimicking its natural 
substrate VP1-2A and ii) APAKE*LLNFD, to enable an in-depth 
structural understanding of polyprotein interaction and enzyme-
assisted cleavage. The enzyme was found to be able to mould around 
its substrate’s residues to display the scissile bond to the active site 
for efficient cleavage, allowing the wide range set of substrates. 
Detailed interactions of the amino acid residues of VP1-2A and 
substituted peptide substrates with the binding cleft are listed in table 
7 and can be visualised in figure 14.  
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a) 
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b) 
c) 
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Figure 14 - PDB ID = 2WV4.Overview of 3Cpro and substrate 
binding. a) Schematic view of the co-crystal structure of 3Cpro 
complexed with the peptide, enzyme represented in ribbon form and 
the bound peptide is shown in cylinder form, colour coded by atom 
type (C, gold). The side chains of the enzyme in the neighbourhood 
of the peptide are shown in turquoise, also colour coded by atom 
type (C, turquoise; N, blue; O, red). b) Expanded into binding site, 
black dashed lines represent interactions between the enzyme and 
ligand. c) Structural representation of peptide substrate P5-P4’, 
Acetyl – Ala – Pro – Ala – Lys – Gln – Leu – Asp – Leu –Phe, 
shown in cylinder form, colour coded by atom type (C, gold; N, blue; 
O, red).    d) Surface representation of 3Cpro complexed with peptide 
substrate c. Electrostatic density represented by colour (red, 
negatively charged; blue, positively charged; white, neutral). 
Position in 
substrate 
Interactions of peptide chain and enzyme 
backbone  
P5            
N-terminus 
 
Is an alanine residue that is reported to be mainly 
solvent exposed. The side chain is a methyl group 
found to be pointing in the direction of the 
hydrophobic protease Met-143 residue, but too far 
for any interaction (4.7Å). Therefore substitutions 
of this amino acid have modest effect on cleavage 
rate. 
P4 Is a proline residue that interacts with what is 
d) 
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reported to be the beginning of the peptide binding 
cleft with side chains of Leu-142 (Cys in the wild 
type), Val-140 and Tyr-190. Part of the residue is 
solvent exposed, therefore not completely bound 
to the binding site. Substitution of this Pro with Ala 
prevented cleavage, however, the authors suggest 
the size of the pocket interacting with the Pro 
should be able to accommodate Ala or Val. 
However, the presence of other residues may 
affect the binding conformation resulting in 
improper presentation of the scissile bond to the 
active site, a possible reason to substrate 
remaining intact. 
P3 Is an alanine residue interacting with Met-143 
residue on the tip of the β ribbon, causing the 
enzyme to alter its conformation on peptide 
binding to allow closer contact with the substrate. 
This position has a range of residues making up 
the natural substrate junctions, provided 
hydrophobic contact is made with β ribbon, 
however, the intensity of the interaction can have 
an effect on other peptide interactions thereby 
affecting cleavage rate. 
P2 Is a lysine residue, whose side chain inserts into 
binding cleft between the β ribbon and the β barrel 
of the enzyme.The side group’s aliphatic chain 
interacts with His-46, the other side interacts with 
apolar side chains of residues Leu-142 and Met-
148. The amino tip of Lys side chain interacts with 
acidic residues of the β ribbon Asp at position 144 
and 146, this amino interaction is reported to be 
necessary for cleavage, absence of the group has 
prevented cleavage.   
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Due to the malleability of the enzyme, the binding 
by this Lys residue causes a positions to change 
in residues Leu-142, Asp-144 and Asp-146 giving 
rise to a pocket labelled S2. 
P1 Is a glutamine residue that was observed to cause 
movements in the backbone of the 
enzyme’spocket. The side chain forms three 
hydrogen bonds to the amide bond of the 
enzymes Thr-158 residue. An identical interaction 
was reported to be observed with glutamate 
substitution, however, one of the H bonds is 
reported to be more distant than seen in 
glutamine, this is described to be due to the loss 
of proton on the carboxyl side chain, thereby 
reducing three strong H-bonding interactions to 
two and increasing pH of the cytoplasm may also 
have a negative impact on binding. The 
substitution of gln to glu causes a two-fold 
reduction in cleavage. 
P1’ Is a leucine residue, whose interaction pocket in 
the only becomes available in presence of the 
peptide substrate. An amino acid with a side chain 
with hydrophobic character is preferred in this 
position to give efficient cleavage, as substitution 
of Leu to Gly has a reduction of ten fold in peptide 
cleavage. The group suggests the residues either 
end of the scissle bond are important in ensuring 
it’s presented optimally to the active site.   
P2’ Is a leucine residue, however, the group have 
reported that a large number of hydrophobic 
residues can be tolerated in this position, as its 
interaction is described to be with a apolar pocket 
of the enzyme. 
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P3’ Is a asparagine residue, that is mostly solvent 
exposed but is able to maintain a H bonding 
interaction with the protease backbone, this 
interaction however, isn’t conserved with other 
natural peptide substrates and therefore thought 
not be necessary. In the synthesis of a FRET4 
peptide substrate, modifications of the Asp side 
chain are reported with coupling to an EDANS 
group, this modification is well tolerated by the 
enzyme, as no change in cleavability is reported.  
P4’ Is a phenylalanine residue, also reported to be 
largely solvent exposed, hydrophobic nature of the 
side chain is reported to have interactions with an 
apolar patch of the upper surface of the protease. 
Amino acids with hydrophobic residues such as 
Arg, Pro and Ala are all well tolerated with minimal 
effect on peptide cleavage.    
P5’          
   C-terminus 
Is a alanine residue, its position is reported to be 
unknown since it made no stabilising contact with 
the enzyme. Furthermore substitutions of this 
amino acid had no effect on peptide cleavage. 
Table 7 - FMDV 3Cpro interaction with natural substrates and mutated 
versions of natural substrate to tests its specificity.78 
 
1.2.4.  Enzyme marker 
The chosen enzyme marker for this project is the highly conserved 
FMDV 3Cpro as more research has been published on its peptide 
interactions, this information allows us to design and synthesise a 
peptide conjugate that can effectively mimic one of its multiple 
substrate interactions as described the enzyme is responsible for a 
large number of cleavages between amino acid pairs during primary 
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and secondary processing, these include; E/G, E/T, Q/L, Q/G, Q/T 
and Q/M, however, not all such protein pairs present in the viral 
polypeptide chain or in the capsid proteins are cleaved by 3Cpro, the 
structural positions may play an important role in recognition and 
cleavage and the need for an extended polypeptide chain in a 
detection probe will be investigated. 
 
Although, the malleability of the FMDV 3C pro discussed in table 7 is 
thought to be the reason for its tolerance for a wide range of natural 
substrates and therefore a suitable target for our project, as the amino 
acids after the scissile bond towards the C-terminus are reported to 
require groups displaying hydrophobic properties and therefore an 
aromatic based chromophore may be able to mimic these interactions 
in the binding cleft and have little or no adverse effect on peptide 
cleavage. Whereas Lpro displays more substrate specificity and 
therefore not considered at this point but its potential as an FMDV 
marker is still to be explored and maybe considered in future work, 
unlike the 2A oligo-peptide sequence that is reported to have no 
protease activity. 
  
1.3.  THE TARGET FLUOROPHORE 
1.3.1.  Principles of fluorescence 
 
Fluorescence is a type of molecular luminescence, the phenomenon  
results from a fluorophore molecule absorbing photons at a specific 
wavelength (energy provided by an external source, typically a lamp 
or  laser) resulting in electronic transitions, the movement of electrons 
can be followed in a Jablonski diagram shown in figure 15, initial 
absorption causes transition of an electron to a higher electronic state, 
the lifetime in this excited state is typically between 1-10 nanoseconds 
 
Chapter 1: Introduction 
 
 
 
 61 
and the decay back to the ground state is coupled with the emission of 
fluorescence.81 
 
 
Figure 15 - A Jablonski diagram showing a simple overview of an 
electronic transition between energy states resulting in 
fluorescence.82 Key: E – Energy, ES1 – Excited state level 1, ES2 – 
Excited state level 2, GS – Ground state and F* - Fluorescence. 
1 –  Absorption of photons causes excitation of electrons 
2 – Internal conversion, energy can be lost via a number of 
routes in order to depopulate the excited state, these routes 
include; collisional quenching, Fluorescence Resonance 
Energy Transfer (FRET) and intersystem crossing (in case of 
phosphorescence not shown on diagram). The quantum yield 
is determined by comparing the number of fluorescence 
photons emitted to the number of photons absorbed.  
3 – Fluorescence emission, due to loss of energy in step 2, the 
wavelength of the photons emitted is of lower energy and 
hence longer wavelength when compared to the excitation 
photons. The difference between the excitation and emission 
energies or wavelengths is described as the Stokes’ shift. 
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1.3.2.  Fluorescence modulation 
Most fluorophores have specific fluorescent characteristics which can 
be followed using a fluorimeter. The use of the fluorimeter is reported 
to be ten-fold more sensitive than a spectrophotometer and therefore 
the preferred detection instrument in this project.83 
 
Small molecule fluorophore scaffolds display unique properties in 
fluorogenic substrates, these properties can be manipulated using 
different chemical strategies to control fluorescence intensity in small 
molecules and are designed to require activation by enzymatic 
activity, light or environmental changes as shown in figure 16; the 
most common method (i) is to covalently attach a group that renders 
the molecule non-fluorescent and fluorescence is restored once the 
group is cleaved by enzyme catalysis or photolysis. The example in 
figure 16 shows that fluorescein is held in its non-fluorescent state 
after acetylation of the phenolic oxygens and conversion to fluorscein 
diacetate. Hydrolysis of the ester groups, catalysed by esterase, 
results in fluorescence generation. In figure 16 (ii) depicts the FRET 
based method which involves two dye molecules, one acting as an 
acceptor and the other a donor. An example of a homo-fret substrate 
assay is shown using boron dipyrromethene as the dye acceptor and 
donor, fluorescence is generated as a result of phospholipase 
activity.84  Non enzyme based methods; (iii) this method involves 
modification of the core structure of the fluorophore to render it non-
fluorescent to undergo some rearrangement to produce a whole 
functioning fluorophore, the example shows trans cinnamic acid 
derivative which undergoes photochemical conversion, specifically a 
isomerisation to the cis form which rapidly forms a lactone, producing 
a fluorescent coumarin.85 (iv) The change of polarity has been 
reported to have an effect on fluorescence on certain dyes an 
example of this is Nile Red, a phenoxazine dye, which in an aqueous 
solution remains non-fluorescent however in a non-polar environment 
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it is strongly fluorescent and is used to stain hydrophobic regions in 
living cells.86 (v) The changes in electronic structure of a dye can 
affect its ability to generate fluorescence. An example of a probe 
utilising this method is Fluo-4 used to measure calcium concentrations 
inside living cells. The lone pair of electrons on the aniline moieties on 
the chelation motif - (1,2-bis(o-amino phenoxy)ethane-N,N,N′,N′-
tetraacetic acid) are capabale of quenching fluorescence via photo-
induced electron transfer. The Ca2+ chelation changes the energies of 
the lone pair of electrons, resulting in less efficient photo-induced 
electron transfer and therefore this energy is lost through 
fluorescence.87,88 
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Figure 16 - Different chemical strategies employed in fluorescence 
modulation.83 
1.3.3.  Small molecule fluorophore scaffolds 
 
Rapid detection and identification of microorganisms is essential in 
many areas of applied and research based microbiology, these 
include – food quality control, health care for humans / animals and 
monitoring in the environment. Many researchers have targeted 
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different microorganisms developing powerful tools in the form of 
enzymatic assays to replace traditional lab-based culture methods.  
The first synthetic substrates reported date back to the early 20th 
century and their structures are based on simple aromatic 
chromophores – nitroaniline and nitrophenol, these are less readily 
used today as they have a similar yellowish colour to microbial 
media.89 A range of synthetic substrates are commercially available 
today and are now regularly used, their chromogenic / fluorogenic 
moiety is often based on derivatives of coumarin, nitro - aromatics, 
fluorescein, nitrobenzofurazane or rhodamine dyes.90 
 
The classic dyes coumarin, fluorescein and rhodamine are utilised as 
popular frameworks for simple fluorogenic molecules. These 
fluorophores can be easily manipulated to a latent form via synthetic 
modifications and designed so fluorescence is generated using 
enzyme activity. Rhodamine and fluorescein in their original forms 
exist in an equilibrium between an open and closed form, the open 
form is highly fluorescent, whilst the closed form is non-fluorescent 
(figure 18) – this is an attractive property when designing fluorogenic 
substrates, following fluorescence manipulation method (i) described 
in figure 16. In 2016, a newer derivative of fluorescein was reported, 
named Virginia Orange (figure 17); this new fluorophore is reported to 
be an exceptional scaffold for both single and dual substrate 
additions. Unlike its parent framework fluorescein, a single substrate 
addition is reported to be sufficient to suppress fluorescence in 
Virginia Orange. The fluorophore can also accommodate two 
independent moieties which can help improve specificity when doing 
target studies, as removal of both groups would be necessary to 
generate fluorescence.91 
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Figure 17 – Structural representation of newer derivative of fluorescein 
- Virginia Orange. 
OH
O
OH
O
O
O
O
OH
OH
O
NH2
O
NH2
O
O
NH
O
NH2
OH
O
'closed'
'closed'
'open'
'open'
R-110 in 
fluorescent form
Fluorescein in 
fluorescent form
Less - fluorescent 
form
Less - fluorescent 
form
(i)
(ii)
 
Figure 18 – Structural representation of equilibrium for R-110 and 
fluorescein in an aqueous solution. 
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For our project we required a fluorophore that is non toxic, cheap, 
commercially available and that has a free amino terminus for a 
stronger amide attachment to the carboxyl terminus of the substrate 
sequence instead of an easily hydrolysable ester linkage thereby 
improving the overall selectivity and shelf life of the probe. In order to 
meet these requirements, we were limited to consider the following 
fluorophores for this project: Coumarin derivatives and R-110 – 
structures in figure 19 and their spectral details and existing 
fluorogenic substrates are described in table 8.  
 
Fluorogenic 
 leaving groups 
Ex 
(nm) 
Em(nm) Example of fluorometric 
enzyme assay components 
7-amino-4-
methylcoumarin (AMC) 
365 455 Substrate-Cbz-Gly-Pro-Arg-
AMC  
Enzyme - Granzyme A92,93 
7-amino-4-
trifluoromethylcoumarin 
(AFC) 
400 505 Substrate-Cbz-Asp-Val-Ala-
Asp-AFC 
Enzyme – Caspase94 
7-amino-4-
carbamoylmethylcoumarin 
(ACC) 
350 450 Substrate-Ac-Arg-Lys-Ser-
Leu-Val-Nle-ACC 
Enzyme - HIV-1 protease95 
Rhodamine 110  
(R-110) 
485 535 Substrate-(Boc-Val-Pro-Arg)2-
Rhod, Enzyme – 
Staphylocoagulase96 
Table 8 – Commonly used fluorophores for synthetic substrate 
assays. Em - Emission wavelength and Ex -Excitation wavelength. 
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Figure 19 – Fluorophore structures – R-110; ε =8x 104 M-1 cm-1 at 
498nm, φ = 0.91 (1),97 AMC,(2), AFC (3) and ACC (4). 
 
R-110 is preferred over coumarin derivatives because it has a higher 
extinction coefficient and fluorescence quantum yield, exhibiting a 
higher probability of energy loss from the excited state via 
fluorescence and not a non-radiative mechanism; this is a desirable 
property as it is capable of improving the overall sensitivity of the 
detection assay, thereby allowing lower concentrations of enzyme and 
substrate to be applied efficiently. Another advantage for using R-110 
as a fluorogenic substrate is that it effectively circumvents inner filter 
effects - a common problem faced in fluorescent assays, as the 
fluorophore is positioned in the red region of dyes with a longer 
wavelength and most organic molecules tend to absorb at shorter 
wavelengths.98 
 
Substrates made using R-110 are commonly synthesised as a 
symmetrical molecule with both amino moieties holding the same 
substrate mimics - usually peptide fragments, this coupling process is 
described by Bywaters et al. as difficult, reflected in very low yields 
and reported to be less amenable to scale up processes and the 
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reason to why Rhodamine fluorogenic substrates are less widely used 
for microbial detection.99 The structure of R-110 implies a bi-substrate 
attachment, necessary for suppressing fluorescence efficiently, most 
commonly in a symmetric fashion; therefore asymmetric substitution 
of the amino groups would require a number of extra steps resulting in 
an even lower over yield.100 Although, the fluorescent mono-
substituted substrate is sought after in some cases, as in 2001, Cai et 
al.  report the synthesis of mono-substitution of the amino group with 
an enhancer moiety to improve cell penetration, N-Ac-DEVD-N0-
octyloxycarbonyl-R-110 and reported the substituted rhodamine 
derivative to be efficiently cleaved by the human recombinant 
caspase-3 and apoptotic HL-60 cells thereby presenting potential use 
in studies of apoptosis inducers and inhibitors. More commonly now 
this red-shift dye is used for enzyme-substrate assays and high 
throughput screening approaches for establishing compound 
profiles.101,102 
 
The acylation / amidation of the free amino groups in the original R-
110 structure locks the dye into a lactone form, in this state the dye 
exhibits no colour and negligible fluorescence (figure 20). The 
zwitterionic nature of the dye in an aqueous solution giving rise to 
fluorescence, this unique property observed is only reported in 
rhodamine, fluorescein and its analogues. 
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Figure 20 – Peptidase activity on R-110 analogues and their 
fluorescence profiles.94 , 95 
1.3.4.  FRET assays 
Another commonly used strategy for protease based assays is FRET, 
this sensitive technique utilises two light sensitive molecules with a 
distance dependant interaction; one fluorescent quenching and the 
other fluorescence emitting. The fluorophore / quencher pair is 
selected so the absorption spectrum of the quencher matches 
emission spectrum of the fluorophore an example of a pair commonly 
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used is EDANS/DABCYL. The rate of energy transfer is determined 
using equation 1.  
𝑘FRET   =     
1
𝑇𝐷
(
𝑅ₒ
𝑟
) ⁶ 
Equation 1– used to calculate rate of FRET and determine transfer 
efficiency. 
TD - decay time of the fluorophore without a quencher 
Rₒ - distance at which FRET is 50% efficient  
r - distance between fluorophore and quencher 
Förster distances have to be sufficiently close and these range 
between 20 - 90Å. 
 
This FRET based enzyme assay has been used over the years to 
facilitate inhibition studies for many 3C proteases from different viral 
pathogens; enterovirus 71,103 rhinovirus 14104 and the Norwalk 
virus.105 In 2007, Jaulent et al.106 utilised the enzyme specificity 
insights reported by Curry et al. in 2005107 as a framework to develop 
inhibitors of the 3Cpro and a continuous based FRET assay for FMDVs 
3Cpro. The assay was used in conjunction with the range of 3Cpro 
inhibitors synthesised to measure the activity of the enzyme being 
targeted. However, prior to this point there is a lack of convenient 
enzyme based assays for 3Cpro. The direction of developing drug-
based inhibitors by the research group was reported to be due to the 
political and technical problems associated with FMDV vaccine 
control, and 3Cpro was described to be their target as it is the principal 
enzyme in polypeptide chain processing to generate the viral 
proteome and therefore an attractive anti-viral target. The group 
synthesised a range of FRET substrates to test kinetics, they 
compared the rate of substrate hydrolysis in presence of the selected 
protease and found that FRET 4 gave the highest turnover rates, its 
structure comprised of a DABCYL group on the N-moiety attached to 
the peptide chain – APAKQ*LLD1FD2LLK, with the EDANS group 
attached to the side chain of the aspartic acid residue (labelled D1- 
closest to the scissile bond). 
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1.3.5.  Synthetic plan for FMDV probe and selection of 
fluorophore. 
Taking into consideration the work published on the structure activity 
relationship of the 3Cpro with a peptide substrate mimic (shown in part 
1.2.3.3, table 7) and the properties of suitable fluorophores for the 
development of the fluorogenic substrates for biochemical testing. We 
initially decided to plan the synthesis of a substrate mimic which 
comprises of a tripeptide sequence Boc-NH-Ala-Lys-Gln-OH attached 
to the N-terminuses of R-110, using the liquid phase peptide synthesis 
(LPPS) analogous to the reported LGX (figure 21) synthesis reported 
by Sinclair et al.104 following the convergent synthetic plan. The 
aromatic nature of our fluorophore was predicted to mimic the natural 
hydrophobic interactions observed between the enzymatic cleft and 
the natural substrates peptide sequence, with this we were hoping to 
test the limits of the target enzymes reported enhanced malleability. 
Commonly fluorogenic substrates are developed to have a tripeptide 
sequence XYZ-F*,108 this is therefore our initial approach to this 
project. 
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Figure 21- Structural representation of the LGX model109 
R-110 is reported to be a superior fluorophore than its coumarin 
derivatives, as it has a higher quantum yield, this property provides 
higher sensitivity in terms of detection and most recently has been 
successfully incorporated in bacterial detection, we therefore hoped to 
transfer this success to FMDV detection by incorporating in our initial 
attempts to synthesise a fluorogenic substrate. 
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Figure 22 - Initial synthetic plan in order to produce the FMDV probe, 
optimum coupling conditions to be determined experimentally. 
Section break - do not delete, change text to white when you are ready to print your final version. 
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2. RESULTS AND DISCUSSION 
2.1.  SYNTHESIS OF FLUOROGENIC SUBSTRATE 
This chapter covers the different synthetic routes attempted in order to make 
ourfluorogenic substrate /detection probe in order to progress on to biological 
testing with the selected target enzyme 3Cpro. 
2.1.1.  Synthetic attempts for total synthesis of the target 
fluorogenic probe (Ala-Lys-Glu/Gln)2-NH-fluorophore. 
2.1.1.1.  Peptide fragment synthesis following a convergent synthetic 
route. 
Peptide synthesis is challenging but can be achieved using different 
techniques; generally small chain peptides are successfully isolated using 
liquid phase peptide synthesis, however, with increasing chain length the 
process becomes more difficult due to the presence and nature of side chains 
that can cause a number of synthetic difficulties due to problems arising 
solubility and purification. The main drawbacks associated with liquid phase 
peptide synthesis methodology isthat it is a time consuming procedure and a 
low yield of the desired polypeptide is often only successfully isolated after the 
series of purification steps involved. Therefore the presence of these side 
chains requires a careful combination of orthogonal protecting groups, 
coupling reagents and racemisation suppressants to be used in         
developing the synthetic plan.110 
 
In 1963, Merrifield first introduced the methodology of solid phase peptide 
synthesis (SPPS)111, a method developed to overcome the problems 
associated with the traditional solution based method. The concept involved 
the peptide sequence elongation on a solid support, where each reaction step 
is followed with filtration of unreacted reagents in the reaction mixture 
alongside any unwanted side products, leaving the desired product attached 
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to the resin, that is cleaved off the resin as the final step of the synthesis. 
SPPS has been widely used since 1963 to make peptide sequences as 
peptide based therapeutics are growing in demand. However, this method 
isn’t compliant with the fluorophores considered in this project as tethering a 
reactive functional group on to the resin would involve attachment of the same 
moiety that would be targeted for peptide elongation. And thereby rendering 
that moiety unusable until it is removed from the resin. 
 
Two general strategies are followed when synthesising sequenced molecules, 
these approaches are the convergent strategy or a linear strategy. The 
convergent strategy is reported to be the chosen approach when dealing with 
complex peptides in solution and involves synthesising separate fragments and 
coupling them together; on the other hand the linear strategy involves a step by 
step addition and is preferred in SPPS. Therefore the convergent strategy was 
the initial approach used to synthesise our target fluorogenic substrate following 
the liquid phase approach, this combination was favoured due to the reported 
ease of purification steps when considering smaller fragments and most 
importantly an improved overall yield of the final product. This approach 
required looking at our target compound as two fragments and devising a 
synthetic plan to couple them together. 
X + Y             X-Y Z + F*            Z-F*         
X-Y-Z-F*
Fragment 1 Fragment 2
Fluorogenic 
substrate
 
Scheme 1 - A schematic representation of a convergent synthetic plan for our 
target fluorogenic substrate, F* = fluorophore, X Y Z – generic letters 
representing amino acids. 
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2.1.1.2.  Fragment 1 synthesis 
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Figure 23 - Coupling of BocAlaOH to Lys(Z)OMe to synthesise the protected 
version of Fragment 1. 
The dipeptide synthesis was optimised using a number of coupling reagents 
listed in table 9 and the best yielding combination was found to be HATU/DIEA 
used for the scale up process, to stock pile the dipeptide for future synthesis. 
Coupling Reagent Percentage yield 
EDC 0% - no reaction progression observed with a series 
of experiments run at different temperatures ranging 
from room temperature to microwave conditions. 
Other variances incorporated in experiments include: 
number of equivalents of the coupling reagent and in 
other experiments the equivalents of base. 
COMU 13.8% 
HATU 25.6% 
EEDQ 15.3% 
Table 9 – Optimisation of fragment 1 and the associated percentage yields. 
21 22 
23 
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Figure 24 - Deprotection of methyl ester of BocNHAlaLysOMe, 24, to give 
BocNHAlaLysOH, 25. 
The deprotection of the methyl ester was achieved under basic conditions in a 
biphasic solvent system of 1:1, THF:H2O mix, this solvent mix is chosen as 
THF is able to dissolve water to 25% v/v this allows contact of the aqueous 
base predominantly present in the aqueous phase with the organic compounds 
dissolved in the organic phase. This biphasic solvent system thereby allows 
nucleophillic attack of the hydroxyl group, thereby removing the methoxy group 
in the form of methanol. The by-product methanol dissolves in the aqueous 
phase and is removed. 
 
2.1.1.3.  Fragment 2 synthesis 
Unfortunately, synthesis of fragment 2 wasn’t as straightforward as fragment 
1, the coupling described in figure 25 encountered problems, discussed in 
2.1.1.4. Initially, we chose to use glutamic acid in place of glutamine as the 
amino acid adjacent to the fluorophore, due to the side chain protected 
versions of glutamine commercially available not fitting the synthetic strategy 
of deprotection when devising a synthetic plan and therefore further steps 
would be needed to reach the target compound. This substitution was 
deemed suitable as it would have minimal effect on the biochemical testing 
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and allow us to move forward to biochemical testing sooner with a sufficient 
amount of product.112 
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Figure 25 - Coupling reaction of fluorophoreR-110 with amino acid: Glutamic 
acid. 
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2.1.1.4.  Different synthetic approaches to synthesise fragment 2 
2.1.1.4.1.  Peptide coupling reagents 
 
Coupling Reagent Outcome 
EDCi 0% - yield, no reaction progression 
observed 
COMU Unresolved via manual purification 
methods– but evidence of coupling via 
TLC analysis. 
HATU Unresolved via manual purification 
methods – but evidence of coupling via 
TLC analysis. 
Table 10 – Different coupling reagents used to improve overall yield of target 
compound. 
Coupling of fragment 2 in terms of ease of handling, and purification proved to 
be capricious in nature, resulting in very low overall yields,this was believed to 
be due to the reactive amino groups on the R-110 being poorly nucleophillicdue 
to intrinsic resonance effects resulting in a mixture of analogues – unsubstituted 
free rhodamine, a mono amino substituted R-110 and bis amino substituted R-
110. A possible reason to why very few rhodamine-peptide based fluorogenic 
substrates are available commercially and in publications, despite R-110 having 
such favourable properties for acting latent in a fluorogenic substrate until 
cleaved in minute amounts.113 
Optimisation of the essential coupling of an amino acid to fluorophore to 
synthesise fragment 2 involved testing a range of coupling reagents, listed in 
table 10 and we found the coupling reagents COMU and HATU to give 
evidence of successful coupling via TLC. To improve target coupling and 
purification, the following changes were applied to the reaction conditions and 
isolation: 
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i) using an excess amount of amino acid was experimented with, in the 
hope to promote reaction completion, however, this wasn’t the case, 
the excess amino acidcaused problems with TLC analysis – a crucial 
tool for investigation, as it significantly increased the amount of 
streaking on the TLC plate usually a sign of overloading a silica plate 
and this was the case even after successive dilutions of the TLC 
sample, this problem translated over to the silica based column 
causing a mixture of components to elute per fraction. After careful 
examination of a series of increased glutamine/ glutamic acid 
reactions it was determined that a slight increase in the number of 
equivalents to 1.2 equivalents per amino moiety being substituted 
was sufficient, provided the excess was removed before 
spectroscopic analysis and purification steps. This was achieved by 
incorporating extra water washes during the solvent extraction work 
up procedure. However, the addition of extra water washes could 
increase number of water molecules in contact with products 
promoting hydrolysis. 
ii) In another effort to improve overall yields of the coupling reaction, 
higher equivalents of base was tested - ranging between 2 – 10 eq. 
for NEt3and DIEA; unfortunately the higher concentration had very 
little effect. Therefore as a more drastic change the stronger base 
sodium hydride was experimented with and again this showed no 
significant improvement in yields. 
Furthermore, purification of the reaction mixture with varying substitutions via 
column chromatography was challenging with the added disadvantage of the 
target compound decomposing when in contact with the commonly used 
stationary phase; silica. This decomposition was initially observed as a change 
from a colourless spot on a silica plate turning a yellow colour over a few 
minutes and was further investigated using 2D TLC. 
2D TLC involved running a TLC plate in its usual way on a square silica plate 
with a spot of the sample being investigated in the corner of the plate. After the 
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sample was run, a vertical line of compounds were visible, the plate wasrotated 
90 degrees and ran again. The second solvent elution spots the compounds 
and the positioning above or below the diagonal line were indicative of 
decomposition as seen with rhodamine based crude mixtures. 
 
Figure 26 – A pictorial representation of a reaction mixture that has 
components that are stable on silica, spots are positioned on diagonal line. 
 
Figure 27 – A pictorial representation of 2D TLC plate of coupling reaction of 
an BocGlu(OBz)OH and R-110. 
Initially, the stationary phase was chosen to be the most commonly used 
material in most labs for column chromatography, namely silica. Silica has 
great separation properties, but on reviewing purification issues and evidence 
of decomposition of our reaction mixture caused by the lone acidic silanol 
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groups it was thought to be advantageous to try other stationary phases; 
alumina and reverse phase silica. Alumina is considered to be milder than 
normal phase silica, with a lower loading capacity and separation resolution 
than silica compared weight by weight. Alumina surface is less polar than silica, 
therefore the eluting solvent was adjusted to be less polar too – 2% 
MeOH:DCM mix from 5% MeOH:DCM mix. However, these TLC plates 
showed similar streaking/ trailing of spots as observed on silica plates, this was 
considered to be down to hydrolysis of the compound when in contact with the 
silica surface. The reverse phase silica is non polar therefore also eliminating 
any catalytic activity that could be responsible for the decomposition observed, 
it requires a polar mobile phase therefore 1:1 ACN:H2O mix was used, results 
showed more intact spots however purification in a saturated aqueous 
environment also resulted in lower yields. 
Another variance tested in order to improve purification and the overall yield 
was different ratios of the eluting solvent mixes and their application on to 
column chromatography. Initially, an isocratic gradient of 1:1 petroleum ether: 
ethyl acetate wasused for resolution, from previous experiments it is known that 
decomposition occurs when exposed to silica for during a purification run, it 
was therefore thought that by increasing the polarity of the solvent mix slowly 
during the run it may help push the samples out of the column quicker thereby 
minimising its contact time with silica and hence reduce chance of 
decomposition, the two solvent mixes that were tested are: 
i) Petroleum ether and ethyl acetate 
ii) Methanol and DCM 
For the first solvent pair the column was initially run at a 1:1 ratio of both 
solvents, the compound separation was visualised using a UV lamp as the 
column began to run and as the bands began to resolve the amount of ethyl 
acetate was increased from 50%-100%. The second set of solvents were 
selected for testing as methanol is commonly used to flush organics of a 
column, therefore the amount of methanol was increased in percent increments 
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from 2% - 5%, the polarity was increased once the separation was visualised 
using the UV lamp. However, it was found that increasing polarity caused more 
overlapping in fractions resulting in the need of repeating the column and 
thereby defeating the purpose of reducing exposure time with the stationary 
phase, even with increased number of fractions being isolated. 
After multiple purification attempts using a range of different variances the 
isolation of the pure disubstitued rhodamine was difficult, although successful 
coupling was apparent at a small scale (25 mg – starting material R-110) by 
TLC analysis, however, the reaction conditions when applied on a larger scale 
failed to produce the disubstituted rhodamine and successful isolation of the 
desired disubstituted rhodamine from the small scale reaction was impossible 
without the use of preparative HPLC.   
As using coupling reagents to gain the disubstituted rhodamine was found to be 
inefficient, in order to gain a good yield of the pure disubstituted rhodamine 
compound, another approach researched was using the retro-synthetic 
strategy. However, despite many applications associated with the fluorophore 
R-110, the synthesis of the main framework of R-110 is described by Grimm et 
al. as being difficult and archaic and therefore this approach wasn’t thought to 
be suitable for the rhodamine based compound.114 The group also 
reportedcoupling to the elusive rhodamine molecule often resulted in less 
efficient acylation, amidation of the amino moities due to it’s nitrogens being low 
in nucleophilicity, as we also established through testing different coupling 
reagents described in this section and so other synthetic approaches for 
fragment two were then sought and are described herein.115 
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2.1.1.4.2.  Buchwald-Hartwig coupling of nitrogen nucleophiles with 
ditriflate fluoresceins. 
 
From an extensive literature search on synthesis of R-110 analogues, another 
route based on Buchwald-Hartwig coupling was found and considered 
noteworthy. This approach was of particular interest because it reported an 
efficient strategy for preparing rhodamine derivatives from fluorescein ditriflates 
from palladium – catalysed C-N cross-coupling with a range of of nitrogen 
nucleophiles including free amines and amides, although bonding to our target 
amino acid isn’t specifically described, this method was trialled to synthesise 
fragment 2 because it involved the cheaper, more readily available fluorophore 
fluorescein (£71.30/g), whereas R-110 (£255/g), prices stated were correct in 
May 2018. Also attention was drawn to this method because the problematic 
amino moieties weren’t already apart of the xanthene framework, illustrated in 
figure 28.116 
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Figure 28 – Structure relationship between xanthene dyes. 
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Triflate  Percentage yield 
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F
F
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61% 
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F
F
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O
O
 
34 
 
 
47% 
Table 11 - Triflation was achieved for a simple phenol and fluorescein 
following method described by Grimm and Lavis.117 Conditions for 33: 
hydroxybenzene, DIEA, trifluoromethansulfonic acid; initial suspension 
prepared at 0°C thenheated to room temperature over 1.5h. Conditions for 
34: pyridine, trifluormethanesulfonic acid; inital suspension prepared at 0°C 
then heated to room temperature for 5h. 
The sulfonation step was followed by the Buchwald-Hartwig coupling, catalytic 
cycle shown in scheme 2, using the amino acid, H-Gln-NH2, figure 29. 
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Figure 29 - Structure of H-Gln-NH2. 
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Although two amido nitrogens are present, the compound was still used as it 
gave two routes of possible binding. Two test reactions were run following the 
reported experimental method, (i) under a N2 atmosphere at 80°C for 3hrs and 
(ii) under microwave reactor conditions for the equivalent of the reported 100°C 
for 18 hrs. However, both test reactions produced the parent compound 
fluorescein through triflate hydrolysis,we found detriflationto bea problem, also 
highlighted by the authors Grimm and Lavis, who have described the unwanted 
competitive side reaction through hydrolysis can be minimised by using a 
higher loading: 10% of Pd and 15% ligand per triflate in the reactant 
compound.107 
Still, even with the increased loadings the same detriflation was observed via 
spectroscopic analysis in our synthesis. Although, this method possibly requires 
trialling different reaction conditions to promote the desired synthetic outcome. 
However, due to lack of reported evidence of it working with our target amino 
acids in literature, in the interest of time and limited resources associated with 
the microwave reactor, alongside the previous failed coupling attempts using R-
110 and it’s framework, the decision was made to research andfollow a 
procedure where glutamine was reported to be attached to a fluorophore or to 
look at further simplifying the synthesis of fragment 2, this was thought to be the 
best choice to complete total synthesis instead of making small changes to the 
variances associated with this method, in order to move on to biochemical 
testing and therefore this method was not further considered. 
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Scheme 2 - The catalytic cycle for Buchwald-Hartwig C-N cross coupling, 
where Lbd is the bidentate ligand, xantphos; MB is the metallic base, CS2CO3; 
Ar is the aryl framework of the fluorescein/rhodamine structures; and OTf is 
the triflate group. 
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2.1.1.4.3.  Substituting complex xanthene dye for a simpler coumarin 
dye. 
 
As a result of the ongoing problems associated with the essential coupling 
reaction of the fluorophore–amino acid, the decision was made to substitute the 
complex xanthene dye (R-110) for a simpler flurorophore, one with a simpler 
frame and a single amino moiety to grow the peptide part of the substrate chain 
from, thereby eliminating problems with purifying an unstable mix of products 
as previously seen with R-110 crude mixtures, the new fluorophore selected 
was AMC, figure 30. 
ONH2 O  
Figure 30– Structure of AMC 
 
2.1.1.4.4.  Peptide coupling reagents  
 
A series of peptide coupling reactions were done in order to identify the best 
coupling reagent of the new fluorophore AMC with the amino acid unprotected 
glutamine, yields of tested reagents are listed in table 12. It was found that the 
coupling was achieved at low overall yields, similar to the rhodamine molecule 
described in section 2.1.1.4.1. The advantages of the AMC over the R-110 was 
the number of products visualised via TLC analysis were less, as expected, due 
to the reduced number of amino moieties present in the AMC fluorophore. 
However, the crude mixture was a brown like slurry that was very difficult to 
redissolve for purification steps even with the use of sonication this was thought 
to be a consequence of the compound being hygroscopic. Eventually via 
preparative TLC fragment 2 was isolated and the final coupling of both 
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fragments was achieved using HATU, a novel probe the fluorogenic substrate 
BocAlaLys(Z)GlnAMC was synthesised and isolated.This compound was 
stored at –5°C in a freezer, however, the compound’s integrity was tested on 
arrival of the biological enzyme a month later, before proceeding on to the 
biological testing phase of the project, using TLC the presence of the free AMC 
(Rf = 0.4, 5% MeOH:DCM) was evident and the need for further purification 
was an option but at the cost of losing more yield. Another problem associated 
with this particular method was that it was found not to be amenable to the 
scale up process to stockpile fragment 2, therefore multiple purification steps 
were deemed unsuitable for this unstable fragment and therefore other 
synthetic routes were explored, discussed in 2.1.1.4.5. 
 
Coupling Conditions Percentage yield 
EDCi 0% - no reaction progression observed with a series 
of experiments run at different temperatures ranging 
from room temperature to microwave conditions. 
Other variances incorporated in experiments include: 
number of equivalents of the coupling reagent and in 
other experiments the equivalents of base. 
COMU 0.57% 
HATU 1.25% 
Table 12 - Different coupling reagents used to improve overall yield of target 
compound. 
 
2.1.1.4.5.  Azide synthesis and selenocarboxylate amidation 
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With the view of changing the poorly nucleophillic aromatic amino moieties 
present in the fluorophore part of the fluorogenic substrate to a different 
nitrogen source, a literature search was conducted on other nitrogen sources 
that can be used in non-nucleophillicamidationmechanisms, this reviewal led 
the project in the direction of azides, as azido moieties are described neither to 
be nucleophillic or basic and their conversion to amide bonds is possible by a 
number of strategies; Staudinger ligation, Williams thio acid / azide amidation 
and the more recently published selenocarboxylate / azide amidation.108 
L. Hu, et al. published significant research efforts on promising methods of 
efficient amidation of aromatic amines using selenocarboxylate / azide 
amidation. The group deduced that selenocarboxylates are more reactive than 
thio acidson comparing selenocarboxylate / azide amidation to thio acid/ azide 
amidation, by specifically comparing reaction progression in the presence of a 
sterically hindered azide, where the thioacid was reported to show no reaction 
progression whereas the selenoacetic acid reacted to form acetamide, 75%, 
shown in figure 31. Therefore the selenocarboxylate / azide amidation route 
was thought to be potentially more capable of facilitating an amidation reaction 
hence selected to improve the yield of our target fluorogenic substrate.118 
N
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Figure 31 – Comparing azide reactions in presence of thio acid and 
selenoacetic acid.115 
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ONH2 O ON3 O
i) pTsOH.H2O
ii) NaNO 2
iii) NaN 3  
Scheme 3 – Synthesis of azido methyl coumarin (AzMC) via an in situ 
diazotisation to generate arene diazonium tosylates followed by azidation.119 
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Table 13 - Azides successfully isolated using experimental conditions 
highlighted in scheme 3. 
The first step involved in the selenocarboxylate / azide amidation route is the 
conversion of the amino moiety to an azido moiety as described in scheme 3. 
The synthesis of AzMC was achieved efficiently with excellent yields at 89 - 
92% by selecting a click reaction route published by Parello et al.116 This was a 
one pot synthesis carried out in water which involved the preparation of the 
intermediate aryl diazoniumtosylate [Ar-N2+TsO-] followed by a instant click 
reaction with the addition of sodium azide producing nitrogen gas and an 
insoluble aryl azide isolated via vacuum filtration. This reaction step was 
successful and confirmed by comparing experimental data to reference NMR 
and melting point data. Also the substitution of an amino moiety (electron 
donating group) with an azido moiety (electron withdrawing group) causes a 
distinct change in the proton NMR spectrum and used specifically as the point 
of investigation was the positioning of the aromatic proton signals in a proton 
NMR spectrum, as the signals move downfield with the same splitting pattern 
as the rest of the aromatic structure remains unchanged. 
The scaling up of the AzMC was easily achieved and carried out to 0.25g, this 
class of molecule required careful storage, as azides are known to be energy 
rich molecules that can be both heat and shock sensitive and are reported to be 
capable of explosively decomposing with little input of external energy.Thesafe 
amount of AzMC (C10H7N3O2) to scale up to was evaluated before 
proceeding,using the guidelines; i) C to N ratio that states the number of N 
atoms in the azide shouldn’t be more than the C atoms and ii) the ‘rule of six’ 
which states that every energetic group such as an azide (diazo / nitro) should 
be diluted by 6 carbon atoms being present in the compound. Using these 
guidelines it was determined that AzMC fit the more - safe category and upto 
20g could be stored of its pure form, as a single azide group was being added 
and characterised.120,121 
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Scheme 4 – A three step, one – pot selenocarboxylate / azide amidation to 
synthesise Nα – protected aminoacyl amino methylcoumarin.122 
After isolation of AzMC was achieved, the first step of the one pot 
selencarboxylate / azideamidation described in scheme 4, involved preparing 
an isopropanol sodium hydrogen selenide (NaHSe) solution via a borohydride 
reduction. This was achieved by following the procedure published by L. Hu et 
al., the group reported isolation of BocGlnAMC, 84%, where the amount of 
NaBH4 was at 1.2 eq. to every equivalent of Se dissolved into solution until a 
colourless solution was produced. This procedure was followed and allowed us 
to isolate BocGlnAMC, at only 4% overall yield.  
 
 
 
Figure 32 – 1H NMR spectrum for AzMC in DMF, aromatic protons 
characterised using 1H-1H COSY 2D NMR spectrum (shown in figure 33). 
47 
48 
46 
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Figure 33 - 1H-1H COSY 2D NMR spectrum in DMSO for AzMC, showing 
interactions used to characterise aromatic protons labelled c and d in figure 
32. 
 
 
Figure 34– AzMC and 1 eq. NaBH4 in DMF, reaction time 5 minutes at room 
temperature, experiment conducted in the NMR tube.  The reduction of the 
azido moiety to the amino moiety is evident. 
 
Chapter 2: Results and Discussion 
 
 
 
 97 
 
 
Figure 35 – AzMC and NaHSe solution, no reaction was observed after 5 
minutes on comparison  to figure 34, reaction time was therefore increased to 
30 mins at room temperature, NMR run after workup, as original reaction 
mixture was saturated with isopropanol therefore reaction mixture was 
washed through celite and concentrated under reduced pressure and 
dissolved in DMF to obtain a comparable NMR spectrum to previous 
runs.The reduction of the azido moiety to the amino moiety is also evident. 
In order to improve the overall yield of BocGlnAMC, the experiment was 
critically analysed and the reduced yield was initially thought to be due to trace 
amounts of oxygen getting into the reaction mixture atmosphere causing 
oxidation to diacylselenides, as carbonyl based selenium derivatives are 
described in literature as being relatively unstable that can undergo 
replacement of the Se atom with an O, N or S atom and convert to a more 
stable C-O bond.123 Therefore, to minimise any loss of unstable 
selenocarboxylate via oxygen presence, the experimental set up for following 
reactions were conducted under an oxygen free, nitrogen abundant 
atmosphere passing through three separate dreschel flasks containing i) 
Feiser’s solution, ii) concentrated sulphuric acid, then iii) sodium hydroxide 
pellets then a CaCl2 packed tube prior to reaching the reaction 
vessel.124However, this intervention didn’t produce the results we expected, the 
first reaction carried out caused no reaction to take place. Further 
experimentation was carried out using this set up and resulted oddly in100% 
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conversion to the original starting material AMC, confirmed by TLC and NMR 
analysis. 
The low percentage yield and the full conversion from an azido to an amino 
moiety was furtherinvestigated and the rapid reduction of the azido moiety to an 
amino moiety was evident via NMR studies in presence of NaBH4, as shown in 
figure 34 and therefore efforts to minimise unreacted NaBH4 were undertaken, 
by reducing the slight excess to equimolar ratios. However, this modification 
had no significant effect in improving yield of the desired compound, therefore 
on further review another point for consideration was that NaHSe itself is also a 
mild reducing agent, therefore a test reaction was conducted with an azide 
being exposed to the NaHSe solution at room temperature. Interestingly we 
found via NMR (figure 35) and TLC evidence of reduction of azido moiety to 
amino moiety too.125 
Moreover, it is known that H2S can cause reduction of azides and of oxidised 
nitrogen species, this conversion is used in fluorescent probes and is accepted 
as a method to detect H2S. H2S has been recently recognised as the third 
endogenous molecule involved in signalling pathways, following NO and CO. 
Their presence is reported to be abundant in most tissues with diverse 
biological uses. H2S specifically is known to be produced mainly by enzymatic 
pathways involving these enzymes; cystathionine β synthase, cystathionine γ – 
lyase and 3-mercapatopyruvate sulphur transferase. Studies have also shown 
that H2S levels can be linked to a number of diseases including Alzheimer’s 
disease, liver damage and diabetes. More recently studies have shown that 
H2S levels can have neuroprotective benefits and maintenance of these levels 
can have therapeutic effects. Therefore researchers have highlighted the need 
to develop detection systems for H2S, as described earlier it is linked to 
numerous physiological and pathological pathways in living organisms, 
however many of their molecular events are still unknown.  Traditionally 
methods of H2S detection included colorimetry, electrochemical assay, gas 
chromatography and sulphide precipitation. More recently fluorescent probes 
based on azido–R-110 have been developed, shown in figure 36.126 
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Figure 36 – Chemical representation of azido- rhodamine analogues. 
Interestingly, this interaction of H2S with azido moieties supports the possibility 
of H2Se a by-product being formed (as shown in scheme 4) that can be 
potentially be responsible for the loss of the reactive azide functionality, as 
selenium and sulfur are two elements that are reported to have both similar 
physical and chemical properties.127 Therefore the chance of H2Se acting in a 
similar reductive manner to H2S in presence of an azido moiety is a plausible 
concept. This specific property for H2Se hasn’t been addressed in literature 
before in this context, however, it is known that hydrogen selenide is a toxic 
volatile gas and in its lowest oxidation state (-‖) is capable of acting as a 
reducing agent and is readily oxidised by oxygen to it’s more 
thermodynamically stable oxidation state Se(0) and water, hence in an oxygen 
free environment the H2Se is still present thereby promoting reduction of the 
azido moiety to amido moiety as was the result of experiment described with 
Feiser’s solution attached. Moreover, the reported pKa value for H2Se is 
reported to be 3.89, therefore dissociation into free positive protons that can 
create an acidic environment would be considered not ideal for promoting 
amidation.128 
In order to minimise loss of the azide functional group due to reduction, an 
alternative approach for the interconversion of carboxyl to selenocarboxylate 
was found in the form of using Woollin’s reagent a selenium analogue of 
Lawesson’s reagent, however the method of producing selenocarboxylates 
wasn’t compliant with retaining the stereochemistry of the glutamine, due to the 
procedure involving reflux at a high temperature for long periods of time, this 
introduces risk of racemisation and therefore not used as retaining 
stereochemistry is crucial for optimal biological interaction. Also this method 
49 50 
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would require complicating an already complex purification by introducing 
stereoisomers, also further reducing the overall yield of the desired product.129 
Additionally, in terms of purification of fragment two, the reaction mixture was 
cleaner with respect to the number of compounds resolved from the reaction 
mixture in comparison to the R-110 based coupling to an amino acid. However, 
the crude product mix was difficult to get in to solution for purification, a range 
of different solvents: MeOH, THF, IMS, ACN, CHCl3, DCM andEtOAc were 
experimented with in order to test the crude products solubility. Pure THF was 
chosen, as it gave the most dissolved compound after gentle swirling, oddly, we 
found that sonication caused more crashing out, NMR verified the material 
crashing out to have identical peaks as seen in the crude NMR spectra. The 
resultant solution of crude products was a kind of brown slurry like consistency, 
the poor solubility displayed by the crude mix presented problems of sample 
loading on to pre-packed silica cartridges used in automated columns or even a 
manual column therefore dry loading was attempted but the compound 
gathered on the bottom of glassware instead of loading on to silica. Instead 
purification was achieved by using preparative TLC (3% MeOH:DCM), where 
the slurry was painted onto the baseline using a modified spotter made out of 
aglass pipette thread through with cotton wool, forming a tip for more precise 
application of the slurry and also it gave better handling of the reaction mixture 
and gave resolution not obtained from manual column chromatography.   
Furthermore, after the purification was achieved, the compound was stored in a 
sealed vessel under a nitrogen atmosphere, at -20°C. However, evidence of 
breakdown was apparent through TLC and 1H NMR analysis (figure 37) 
through testing before progressing on to coupling to fragment 1. On comparing 
the experimental methods of synthesising fragment 2, it was noteworthy that 
the selenocarboxylate/ amidation method gave the highest overall yield of 
fragment 2 when comparing to peptide coupling reagents described in section 
2.1.1.4.4. Although this method was also found not to be amenable to process 
chemistry, instead stock piling of fragment 2 was achieved by repeating a 
series of experiments until 7.4 mg of pure BocGlnAMC was isolated and 
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progressing on to the final coupling step using the most efficient of the coupling 
reagents tested, namely HATU. 
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Scheme 5 – The mechanism for reaction of selenocarboxylates with AzMC130 
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Reproducibility of the selenocarboxylate amidation experimental procedure 
wasn’t consistent and was found to be unsuitable in terms of the scale up 
process. Furthermore, the handling of the compound was problematic 
when purifying, as the crude mixture presented solubility problems and 
continuosly crashed out of solution when trying to purify, this solubility 
problem was an issue in both methods of peptide coupling reagents and 
selencarboxylate / azide amidation process. In order to stock-pile the 
fluorogenic substrate for biochemical testing, the structure was critically 
analysed and modifications were made in protecting groups in order to 
improve stability shown in figure 38.  
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Figure 37– Expanded version of proton NMR spectrum of samples, a) Pure 
BocGlnAMC, 55 and b) BocAlaLys(Z)GlnAMC, 56 and free AMC,  the region 
magnified  in b) confirms the presence of two compounds alongside TLC 
visualisation(RF values 0.12 and 0.4 respectively, 5% MeOH:DCM) as there are 
now two signals resonating in area of vinylic proton that is neighbouring two 
quarternary carbons, labelled as position 3. 
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2.1.1.4.6.  Protection strategy altered to overcome substrates solubility 
and purification issues. 
O
NH
ONH
NH
O
O
O
O
O
O
NH
O
NH
NH2
O
O
NH
ONH
NH
O
O
O
O
O
O
NH
O
NH
NH
O
Structural modifications made 
to improve solubility and 
protecting groups chosen to 
comply with universal 
deprotection method 
Free amide moiety, 
protection of which 
may help improve 
solubility. The Cbz group isn't acid 
labile and requires 
hydrogenation for 
deprotection of the amine 
moiety.
Boc groups attached 
are acid labile and 
chosen method for 
deprotection.
The trityl group is acid 
labile, more stable than 
boc groups therefore 
found to require stronger 
acidic conditions to cleave 
them.
The acid labile protecting 
- boc group
After reviewing potential 
protecting groups, the 
trityl group was chosen 
due to its bulky and 
stable nature and it was 
noted that its presence 
should improve 
solubility without having 
to use a solvent mix that 
is largely made up of 
polar solvents.  
 
Figure 38 – Protecting group modification highlighted for the target 
fluorogenic substrate.131 
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A literature search was done to find appropriate reaction conditions to facilitate 
global deprotection, thereby reducing the number of deprotection steps and 
preserving the structural integrity and the substrates overall yield. Although, 
from previous synthetic steps it is known that the target compound is unstable 
and acid sensitive, to address this instability experiments were undertaken to 
determine the lowest possible acid concentration needed to deprotect both the 
trityl protecting group and the boc groups.   
Trityl deprotection of ethers are more widely reported than of amides. In 2001, 
A. Pathak et al. specifically reports working with acid sensitive compounds and 
reports successful detritylation, by using between 1% - 5% TFA and running 
through a silica gel column to get pure detritylated deoxynucleosides and 
pentoses.132 As a starting point this method was used to deprotect the 
BocGln(trt)OH, however, global deprotection was not achieved. The amount of 
TFA was slowly increased as it was determined that the amino-trityl group was 
significantly more stable and required a stronger acid to cleave them.133 Testing 
higher acidic concentrations found that 1:2:0.1 chloroform:TFA:water and 
passing through a silica plug and immediate drying under reduced pressure 
was efficient in achieving boc removal and detritylation of BocGln(trt)OH to give 
NH2GlnOH, this was verified using proton NMR, where the loss of a boc group 
involved the loss of a singlet peak at 1.45 ppm integrating for 9H and loss of a 
multiplet at 7.19 – 7.33 ppm integrating for 15 protons as shown in figure 39. 
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Figure 39 - a) 1H NMR of BocGln(trt)OH in CDCl3, TMS b) 1H NMR showing 
the removal of both protecting groups of BocGln(trt)OH, full NMR spectra 
data attached in the appendix c) 1H NMR of trityl group crashed out on to the 
silica plug wash using water. 
To improve the overall yield of the fluorogenic substrate, the synthetic strategy 
was modified from the original plan of using the convergent strategy described 
in scheme 1 to the modified plan of using the linear strategy as decribed in 
scheme 6. To accelerate synthesis the decision was made to source in a 
custom-made peptide of sequence; BocAL(Boc)Q(Trt)OH, synthesised using 
an automated peptide synthesiser by Sigma Aldrich and purified using 
preparative HPLC. 
 
 
Chapter 2: Results and Discussion 
 
 
 
 108 
X-Y-Z F*         
X-Y-Z-F*
Fragment 1 Fragment 2
Fluorogenic 
substrate
 
Scheme 6 – Schematic representation of the new linear strategy adopted, 
where: X, Y and Z are generalised symbols for amino acids. 
The tripeptide was coupled to the AMC using peptide coupling conditions 
optimised and described in table 14. 
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Introduction of the trityl group on to the glutamine’s side chain increased the 
stability and solubility of the compound, thereby improving the handling of the 
compound during the purification process. Problems with loss of yield during 
purification due to crashing out and decomposition on silica as observed with 
the substrate BocAL(Z)Q-AMC was overcome by the addition of this bulky 
protecting group. However, the overall yield was still very low, due to the 
59 
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reliance of the final coupling on a coupling reagent, a problem faced throughout 
the project. 
Furthermore, as it has been determined through deprotection studies on 
BocGln(Trt)OH discussed earlier in 2.1.1.4.6 that the BocAL(Boc)Q(trt)AMC 
also requires acid treatment in order to deprotect the substrate ready for 
biochemical testing. From previous experiments it is also known that the 
unprotected tripeptide sequence is unstable therefore the ideal situation for the 
biochemical testing of this compound would be, to achieve its deprotected 
status in presence of the target enzyme to minimise any premature 
decomposition, this was tested and reported as a DSF study in chapter 3.  
 
Fluorogenic substrate successfully 
isolated 
Overall yield 
Boc AL(Z)QAMC, 60 0.4% 
Boc AL(boc)Q(trt)AMC, 61 15.7% 
Table 14 – Fluorogenic substrates successfully isolated and their overall 
percentage yields. 
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3. BIOCHEMICAL TESTING 
3.1.  CHAPTER AIMS 
i) Determine purity of the enzyme sample extracted from clinical 
sample 
ii) Determine optimum conditions for biological assay 
iii) Biological testing of the conjugated probe to gain proof of principle 
iv) Test selectivity of detection probe in a clinical model and against 
other enzymes with similar activity. 
v) Compare the AMC detection probe shelf life with a commercially 
available detection probe. 
 
3.2.  SDS-PAGE ANALYSIS OF 3C PROTEASE 
3.2.1.  Materials and method 
3Cpro was kindly provided by the Pirbright Institute in Surrey (volume of 100 
µL at concentration of 13.8 µM). Details of the mutations in the supplied 3Cpro 
strain are C95K and C142A, these substitutions are reported to improve 
solubility and proteolytic activity respectively.134 The enzyme was stored at-
80°C on arrival and thawed to room temperature for biological assays. 
 
To verify the purity of the enzyme sample we received from the Pirbright 
Institute, the technique SDS-PAGE was used. The gel was run in a 
MiniProtean Tetra system (BIO-RAD) with a SDS running buffer (National 
Diagnostics). The acrylamide gels consisted of a resolving gel and a stacking 
gel of concentrations 12% w/v and 6% w/v respectively. The protein sample 
was prepared by adding a loading dye in a 1:1 volume ratio (Table 15). The 
sample mix was denatured by heating at 95° for 5 minutes to ensure protein 
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conformation had no effect on the protein migration through the gel and the 
distance travelled can then solely be attributed to the molecular weight. 20  µL 
of the protein sample/ loading dye mix was added to the well and run 
alongside the molecular weight marker ECL Full-Range Rainbow molecular 
weight marker (Amersham) in a neighbouring well. Electrophoresis was run 
under 180V for 60 minutes (BIO-RAD PowerPak 300). The gel was stained for 
30 minutes in a 1% w/v Coomassie Blue solution at room temperature under 
gentle shaking conditions: 90 RPM. The gel was then rinsed with water and 
de-stained using 10% v/v ethanol, 10%v/v acetic acid for 17 hours at room 
temperature under gentle shaking conditions: 90 RPM. The destained gel 
imaged using a Geldoc XR+ (BIORAD). 
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Materials Components Concentration of 
each component 
Resolving 
gel 
Acrylamide: bis acrylamide (37.5:1) 
SDS 
Ammonium persulfate  
Tetramethylethylenediamine 
(TEMED) 
Tris-HCl 
12% v/v 
0.125% w/v 
0.05% w/v 
0.002% v/v 
 
390 mM 
Stacking 
gel 
Acrylamide: bis acrylamide (37.5:1) 
SDS 
Ammonium persulfate 
TEMED 
Tris-HCl 
6% v/v 
0.125% w/v 
0.05% w/v 
0.002% v/v 
116.6mM 
Loading 
dye 
Sucrose 
Bromophenol blue 
Dithiothreitol (DTT) 
40% w/v 
0.25% w/v 
5 mg/mL 
SDS 
running 
buffer 
Tris 
Glycine 
SDS 
0.25M 
1.92 M 
1% w/v 
Staining 
solution 
Ethanol 
H2O 
Acetic acid 
Coomassie brilliant blue 
50% v/v 
40% v/v 
10% v/v 
0.1% w/v 
Destaining 
solution 
H2O 
Acetic acid 
Ethanol 
80% v/v 
10% v/v 
10% v/v 
 
Table 15- Materials used for SDS-PAGE. 
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3.2.2.  SDS-PAGE Results 
 
 
 
 
Figure 40 - Image of SDS-PAGE: the molecular markers were run in the left 
lane, marked as ‘M’ and the 3Cpro in the right line, marked as ‘1’. The streaky 
nature of lane 1 is due to the enzyme sample being in a high concentration of 
salt. The 3Cpro (MW = 23kDa) stained a band adjacent to a faint band of the 
molecular weight ladder of 24kDa.135 
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3.3.  DIFFERENTIAL SCANNING FLUORIMETRY (DSF). 
3.3.1.  Materials and method for DSF 
Following an adapted protocol reported by Niesen et al.136 pepsin was diluted 
to 64µg/mL in PBS pH 7.4, 0.5mM EDTA and 5x Sypro Orange (Oxoid). The 
fluorescence was measured using an Mx3005p qRT-PCR (Stratagene), the 
temperature was increased from 25˚C to 95˚C at an increment of 1˚C/minute. 
Spectral properties used for detection of Sypro Orange; excitation wavelength 
at 300/472 nm and the emission wavelength at 570 nm.Data analysis was 
completed using software tools obtained from the Structural Genomics 
Consortium Oxford (ftp;//ftp.sgc.ox.ac.uk/pub/biophysics). The raw DSF data 
was fitted to the Maxwell-Boltzmann distribution in Graphpad Prism to 
determine the TM value. 
 
Enzyme Extracted from Use Supplier 
Pepsin Porcine stomach 
mucosa 
Testing 
parameters for 
detection assay 
with TCA 
Sigma Aldrich 
Table 16 - Biological material for TCA study. 
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3.3.2.  Investigating parameters needed for the enzymatic 
assay of detection probe. 
In order to define the parameters needed for the unstable detection probe in 
the enzymatic assay, DSF was employed as a technique to monitor the 
effects of the percentage TCA on an enzyme; the plan was to establish a 
balance between maintaining the protein’s structure whilst providing a suitable 
environment needed for the deprotection of the protecting groups attached to 
the detection probe. These conditions would allow the deprotection of the 
detection probe to occur in the presence of its target enzyme, therefore 
eliminating risk of the probe decomposing before having contact with its target 
enzyme. 
 
Thermal stability of the protein was tested by adding the dye (Sypro Orange) 
which binds to the hydrophobic parts of the enzyme as it denatures with 
increasing temperature. The intensity of the fluorescence detected by DSF is 
directly proportional to how effectively the dye is bound therefore the 
temperature at which the protein denatures is ascertained by the increase in 
fluorescence. 
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3.3.3.  DSF Results 
 
Figure 41 - Measuring the effects of TCA on the thermal melt curve of the 
common enzyme pepsin.The changing percentages of acid are: A (control), 
0% TCA; B, 1% TCA; C, 0.5% TCA; D, 0.25% TCA. 
 
Figure 41 represents the changes in thermal stability of the enzyme pepsin 
and emission of fluorescence by Sypro Orange. The data shows a significant 
reduction in stability of the protein in the presence of all tested TCA levels 
therefore TM value: 50°C ±0.5°C could only be determined from curve A- the 
acid free sample. These results show the addition of an acid to the detection 
based assay would not be suitable as the enzyme is significantly destabilised 
even at the lowest 0.2% TCA tested, decreasing the acid percentage further 
would not be sufficient for deprotecting the boc and trityl protecting groups 
attached to the amino acid sequence of our detection probe. Therefore the 
deprotection step was designed to precede the enzymatic assay.  
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3.4.  DIAGNOSTIC PROBE TESTING 
3.4.1.  Materials and method for probe testing 
The activity of the 3Cpro in the presence of the conjugated detection probe 
was monitored using fluorescence. A triplicate series of assays were 
completed initially to gain optimum conditions for both the substrate and the 
enzyme, the results obtained were used to gain proof of concept. All enzyme 
assays were carried out in Nunclon 96-well flat transparent plate at volume 
100 µL/well. The details of the assays are listed in appendixtables 1 – 5 the 
assays were run in triplicate or duplicates (the latter due to limited amount of 
3Cpro enzyme). Fluorescence readings were taken on the Infinite M200 PRO 
plate reader and the parameters were set to: excitation wavelength of 360 nm 
and at the emission wavelength of 455 nm in order to analyse the release of 
the fluorophore AMC.  
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3.4.2.  Proof of concept testing. 
3.4.2.1.  Fluorescence results  
a) 
Initial Biological Testing, one–way anova data and Dunnett’s Multiple 
Comparison Graph. 
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Figure 42 – The graph represents the fluorescence data from biological 
testing, after 10 minutes of incubation at 37°C, one-way ANOVA data and 
Dunnett’s multiple comparison test results, both these tests were run on 
Graphpad 6, the Dunnett’s multiple comparison datais represented using 
asterixes (*), where the more significance is marked with more asterixes.1: 
control, 2: G; [E] = 1.38µM, 3: H; [E] = 13.8µM, [S] was controlled in all wells. 
The full details of concentrations and volumes used are in the appendix table 
1. The error bars represent the standard deviation of replicates (n=3).  
On analysing results in figure 42, a significant statistical difference was seen 
using the one-way ANOVA test between the negative control and the testing 
wells (p<0.0001) indicative of a significant change in fluorescence 
measurements.  Further statistical analysis using the Dunnett’s multiple 
comparison testwas performed to determine significance from the negative 
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control and each testing well, this is represented in the graph shown in figure 
42. So from the Dunnett’s multiple analysis we found the higher [E] of 
13.8µM and 10 minute incubation caused a more significant change in 
fluorescence when compared to the ten fold less [E] of 1.38 µM with the 
negative control wells, therefore the higher concentration and volume of  
3Cpro was used in furher assay tests. 
After proof-of-concept testing, further fluorescence generation studies were 
planned to gain a better understanding of 3Cpro, therefore particular interest 
was in recording initial kinetic data, in order to define an enzymatic model for 
the target protease and compare to the established Michealis-Menten (MM) 
Model in order to define the enzyme’s kinetic parameters. 
In the interest of gaining a better understanding of our target enzyme, it would 
have been ideal to use a larger spread of [S], ranging between 0-150 µM. 
However, from the initial biological testing it was determinedthat 50µM didn’t 
show any fluorescence generation and therefore was not considered further 
due to limited supply of the target enzyme and the unstable nature of the 
detection probe once deprotected. 
 
Furthermore, on progression to the enzyme kinetics study it was apparent that 
the fluorescence measurements at time=0 were slowly increasing over time, for 
the stored substrate solutions. An increase for the [S] at 100µM from ~1000 
RFU (in figure 42) to ~2000 (in figure 43) RFU was seen after 4 hours in buffer 
solution. This was thought to be due to the detection probe decomposing, 
releasing the free fluorophore and highlighting a major problem with stability, an 
issue faced throughout the synthesis and purification part of the project. 
Eventually, no change in fluorescence measurements was being recorded, 
indicating no substrate hydrolysis, as a possible result of the inevitable 
denaturation of the target enzyme or the decomposition of the unstable probe. 
Unfortunately, sufficient number of assays weren’t completed in order to define 
the kinetics of the FMDV protease enzyme mathematically; however, further 
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evidence of cleavage in the presence of our target enzyme has been gained 
through increased fluorescence, as seen in figure 43 at substrate 
concentrations of 100µM and 150µM, this increase in fluorescence was found 
to be a significant change in comparison to the negative control using the one-
way anova statistical method (p<0.005). 
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Figure 43 - Performance testing results represented as fluorescence 
generation in the presence of the target enzyme, 3Cpro, [E] = 13.8µM. The 
error bars represent the standard deviation of replicates (n= 3). 
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3.5.  SELECTIVITY TESTING OF THE DETECTION PROBE. 
3.5.1.1.  Biological materials for selectivity testing 
Enzyme Extracted from 
Trypsin type 1 Bovine pancreas 
Chymotrypsin type 
2 
Bovine pancreas 
Thrombin Bovine plasma 
TEV protease Recombinant expressed in 
Escherichia coli 
 
Table 17 - Biological materials for selectivity testing. All enzymes were stored 
at -5 to -20°C and thawed to room temperature before running biological 
assays. 
To further test the application of the detection probe, a series of experiments 
were designed to expose the conjugate to other proteases that may be found 
in a clinical sample taken from livestock infected with FMDV. The 3Cpro 
enzyme is reported to have properties characteristic of cysteine and serine 
proteases, therefore the following commonly occurring serine type proteases 
were selected to test against: chymotrypsin, thrombin and trypsin. Also to 
specifically test the amino acid sequence attached to the fluorophore another 
enzyme was selected: Tobacco Etch Virus (TEV), as this is a related cysteine 
protease with a Q/G and Q/S selectivity similar to that mentioned for 3C 
protease in section1.2.3.3; this shows the importance of this protease when 
testing selectivity, although the consensus sequence for TEV is Glu-Asn-Leu-
Tyr-Phe-Gln.137 
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3.5.1.2.  Results from selectivity testing 
 
Figure 44 – Selectivity testing results represented as fluorescence generation 
over time. Enzyme assays made up of the substrate = (ALQ-AMC) 100µM, in 
presence of the selected enzymes: Chymotrypsin, Trypsin, Thrombin and 
TEV protease 15µM. The error bars represent the standard deviation of 
replicates (n=3). 
 
0
100
200
300
400
500
600
700
0 2 4 6 8 10
R
e
la
ti
ve
 F
lu
o
re
sc
e
n
ce
 U
n
it
s
t (min)
Chymotrypsin TEV protease Trypsin Thrombin Control
 
Chapter 3: Biochemical Testing and Conclusion 
 
 
 
 125 
 
Figure 45 – Graph of normalised data between 0-400 to show 
comparison of all enzymes tested with substrate (ALQ-AMC) with 3Cpro. 
Concentrations for enzymes between 13.8µM - 15µM and substrate 
100µM. 
 
 
From figures 43 - 45, it can be deduced that the detection conjugate 
breakdown has shown selectivity to the 3Cpro enzyme over commonly 
occurring enzymes in clinical samples, also the TEV protease, was found to 
have no significant change in fluorescence measurements recorded in 
comparison to the negative control using the one-way anova statistical 
method (p>0.05). Furthermore the duration of time fluorescence measurement 
was chosen to be the same length as the assay experiments run with the 
target enzyme 3Cpro reported earlier, as in the presence of the 3Cpro, 
fluorescence would be generated more rapidly and therefore a delayed 
increase in fluorescence would be indicative of breakdown of the conjugate 
via other routes. 
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3.6.  STABILITY TESTING OF AMC DETECTION PROBES. 
 
The stability of the AMC probe became a point of investigation, as it has been 
a major problem throughout this project. Where specifically decomposition 
has been observed during purification steps and storage handling, therefore it 
can be deduced that unusually the amide bond is prone to autohydrolysis, the 
increase in initial fluorescence between readings from 1000 RFU to 2000 RFU 
over a period of 4 hours was indicative of the detection probe breaking in     
5% v/v DMSO:PBS buffered solution mix with a resultant increase in free 
AMC concentration without enzyme assistance. This substrate decomposition 
was thought not only due to autohydrolysis but was also thought to be a 
consequence of trace amounts of TFA in the assay. As the preceeding 
deprotection step involves the removal of the orthogonal protecting groups 
(boc and trityl) by exposure to TFA, this is removed under reduced pressure, 
prior to making up substrate concentrations for biochemical assays. So trace 
amounts of TFA could be trapped in the sample which when reconstituted in 
DMSO and the aqueous buffer can cause acidic degradation. Degradation 
would occur via hydrolysis of amide bonds over time of the main backbone of 
the substrate, in the absence of the acid labile protecting groups. An acidic 
environment would also have an affect on the structural integrity of the target 
enzyme, thereby reducing activity, a consequence determined from earlier 
studies of TCA presence on the more common and readily available enzyme, 
pepsin.  Moreover, the presence of trace amounts of TFA coupled with the 
increasing temperature to meet the optimum temperature of 37°C of the 3Cpro 
enzyme, giving extra thermal energy to the detection probe otherwise stored 
at -80°C, to prevent decomposition, could also be contributing to the 
breakdown of the substrate molecule. 
 
Furthermore, a separate study was conducted on a comparable, commercially 
available, well documented and robust AMC based detection probe, 
BocValProArgAMC for the target enzyme thrombin. This specific probe was of 
interest because like our novel probe, AlaLysGlnAMC, is also based on a 
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tripeptide sequence although with a completely different sequence and 
biological target. Due to the difference in specificity the probes were only 
comparable in their sample preparation and shelf-life. To test the shelf life of 
the established probe, biochemical testing of BocValProArgAMC with 
thrombin was completed and the Michaelis- Menten parameters were 
determined and are defined in figure 45.  
 
On comparison of the solubility of the probes BocValProArgAMC and 
AlaLysGlnAMC, it was noted that the established probe was sourced in as its 
hydrochloride form and could be dissolved in pure buffer solution, PBS, unlike 
thenovel probe that required 5% DMSO to stay in solution. Also, it was noted 
that the activity of the established probe’s sample didn’t change by much after 
1 month of storage in a freezer at – 20°C and the biological enzyme at - 80°C, 
determined by comparing fluorescence at time 0 of the control wells and the 
calculated MM parameters (table 19), both of which didn’t show a significant 
enough change through one-way anova statistical test (p>0.05). Whereas our 
novel probe showed evidence of decomposition through comparing initial 
fluorescence measurements described earlier in section (3.4) only a few 
hours after assay preparation. 
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A major difference can also be noted between the two probes in the amounts 
of volume and concentration required to gain significant fluorescence 
response, as a higher concentration of both the S and E is needed by our 
novel probe (appendix table 2) in comparison to commercially available 
detection probe for Thrombin (appendix table 5).  
 
Set Km (µM) Vmax (µM/s) 
1 150.11 3.5 
2 152.24 3.9 
 
Table 18 - The MM parameters are tabulated for the enzyme assay sets run 
a month apart for thrombin in presence of Boc-VPA-AMC. 
In order to determine the rate of fluorescence emission from the cleaved 
fluorophore AMC and the Michaelis Menten (MM) parameters of thrombin, 
kinetics were measured through the fluorescence data, using the 
spectrophotometer. Graphs were plotted as fluorescence vs time for each 
concentration and the gradient (rate) was determined using the straight line 
equation: 𝑦 = 𝑚𝑥 + 𝑐 (Equation 2). The average of the rate of the multiple 
(triplicate) data sets was then plotted against [S] and fit against the MM 
model. The kinetic data for thrombin was fit to the Michaelis Menten (MM) 
model and further analysed to determine the MM parameters graphically. 
 
 
𝑣 =
𝑉𝑚𝑎𝑥 .  [𝑆]
𝐾𝑚 + [𝑆]
 
Equation 3, MM equation, where; 𝑣, the initial velocity of the reaction; 𝑉𝑚𝑎𝑥, is 
the maximum velocity; [S], Substrate concentration and 𝐾𝑚, is the dissociation 
constant for substrate, also described as the Michaelis-Menten constant. 
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Figure 46 – Comparing experimental data for thrombin in presence of Boc-
VPA-AMC to mathematical model.The blue curve represents the mathematical 
model generated using the MM equation. The red data points represent the 
experimental data. This graph shows a good correlation of the data points with 
the curves indicating activity of thrombin is of Michealis nature, as is 
known.The MM parameters ascertained from the graph are KM = 150.11µM 
and Vmax = 3.5µM/s 138 
 
3.7.  CONCLUSION AND FURTHER WORK 
The total synthesis of the detection probes: BocAL(Z)Q-AMC and 
BocAL(Boc)Q(Trt)-AMC were successfully achieved after trialling a range of 
different synthetic routes. Although, rhodamine is described to be the more 
superior fluorophore for a latent enzyme-based detection system based on its 
physical chemical properties, from the results obtained and discussed from 
the synthetic work done in this project, the overall consensus was reached in 
agreement with other researchers, that synthesising rhodamine based 
detection probes is capricious in nature, due to its low nucleophilicity of amino 
moieties caused by intrinsic effects and difficulties associated with building 
upon the main framework is the possible reason to the lack of commercially 
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available rhodamine based detection probes and also the reason to the 
change of direction in this project to a more simple fluorophore, AMC.139  
 
Here I have described briefly the methods that failed to produce isolatable R-
110 based detection probes, this includes the conventional peptide coupling 
reagents; COMU, EDCi and HATU. An alternative method was also 
attempted, using Pd catalysed C-N cross coupling, where the starting material 
involved the more readily available fluorescein. However, the success 
reported by Grimm et al. wasn’t mirrored in the case of attaching our target 
amino acid Q to the fluorophore.140 Instead, autohydrolysis of the ditriflate was 
encountered multiple times, a problem circumvented by the authors by 
increasing Pd loading, however this wasn’t the case in our experiments.  
 
Still following the original plan of convergent synthesis; after an extensive 
literature search, a method was found that specifically described the synthesis 
of part of our AMC based target compound (fragment 2) via a 
selenocarboxylate / azide amidation route. Following this method the 
synthesis of BocQ-AMC was successfully achieved and isolated supported by 
spectroscopic analysis. However, this method also had its limitations, the 
overall yield achieved was relatively low ~ 5%, also the method was found not 
to be amenable to the scale up process and the target compound BocQ-AMC 
was found to be unstable determined through its decomposition during 
purification and on storage, verified by TLC and fluorescence measurements. 
 
Also noted, through experimentation of this method was a possible reductive 
link between the different reactants in the reaction mixture resulting in the 
reduced overall yield of fragment 2: sodium borohydride a strong reducing 
agent, therefore used at equimolar ratios; sodium hydrogen selenide a mild 
reducing agent, supported by NMR analysis and hydrogen selenide a possible 
side product but also a possible reducing agent of azido moieties, all of which 
contribute to the reduced overall yield of the target compound.  
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In order to stock pile a more stable compound for biochemical testing, the 
following changes were implemented: A trityl group was introduced to the 
structure, to improve on the solubility, stability and the overall yield. A linear 
strategy was successfully used to synthesise BocAL(Boc)Q(Trt)-AMC of yield 
~15%, supported by spectroscopic analysis. Although a stable compound was 
formed, deprotection of the compound would reintroduce the instability 
observed in earlier reactions. Therefore the idea of deprotecting the detection 
probe in presence of the enzyme was tested and it was determined using 
DSF analysis that the acidic deprotection of the boc and trityl group in the 
enzymatic assay would compromise the enzyme’s structural integrity, 
therefore deprotection was carried out as a separate step before the 
enzymatic assay. 
 
The purity of the enzyme sample received was verified, to ensure no 
biological impurities were present in the enzymatic assay, the purity was 
verified using SDS PAGE analysis, a single band of the expected weight of 
23kDa was found.  
 
From the biochemical testing the proof of breakdown has been gained of our 
detection probe as a consequence of our target enzymes activity. The 3Cpro 
also displayed selectivity for the detection probe when tested over other 
commonly found enzymes in FMDV clinical samples: chymotrypsin, thrombin, 
trypsin and the TEV protease. From the results obtained it can be concluded 
that our detection probe is recognised by the 3Cpro and the enzyme is capable 
of recognising and processing shorter fragments of peptides, previously 
reported not to be the case.141 
 
Despite the stability of the detection probe causing problems throughout the 
project, we can confidently conclude the cleavage of the free fluorophore was 
enzyme-assisted and not due to spontaneous decomposition as the 
measurements recorded from the control wells (enzyme-absent well) 
remained constant, further verifying the release of the fluorophore in enzyme -
containing wells to be enzyme-assisted. 
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However, the deprotected detection probe was found to have a short shelf-life 
in comparison to a commercially available AMC probe, this limits its use and 
increases chances of false positive results, unfortunately rendering the probe 
commercially useless, in this state. Although the imminent need of a rapid 
detection probe has been highlighted in this project and the recognition of the 
smaller peptide fragment by 3Cpro has been proved, further work on the 
stability of the detection probe can potentially provide a more commercially 
viable detection probe.  
 
On reviewing the results gathered from this project of the synthesised and 
biologically evaluated detection probe, the two major areas for further work in 
order to implement a commercially viable detection system are; stability and 
sensitivity. These points have been discussed herein: 
 
- Improving the stability of the detection probe and thereby 
relatively increasing the shelf-life. The target amino acid 
sequence of ALQ - although proved to be recognised by 3Cpro, is 
known to be unstable through our experimental results when 
attached on to the AMC fluorophore, during synthesis, 
purification and storage. From research published on 3Cpro; the 
enzyme is known to accept a range of substrates and is 
therefore described to have the enzyme property of it being 
malleable.142 This property can allow a trial of a number of 
different tripeptide sequences in order to develop a more stable 
and thereby more useful substrate-fluorophore conjugate for a 
deployable detection system. 
- After improving on stability of the detection system, it would be 
useful to get information on the methods sensitivity by 
performing comparative studies against the reported ‘gold 
standard’ – portable PCR.  
- Improving the sensitivity of the dye system by substituting the 
simpler, well known coumarin dye – the AMC fluorophore for a 
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more superior fluorophore. As reported by many authors, the R-
110 is described to have superior fluorogenic properties such as 
higher quantum yield and a higher extinction coefficient than the 
AMC coumarin dye, therefore having a detection probe with this 
xanthone based fluorophore would improve the probes 
sensitivity. However, from synthetic work in this project we have 
found simple coupling on to the R-110’s free poorly nucleophillic 
amino moieties in a symmetric mode is capricious in nature. 
Therefore substituting the coumarin dye to a fluorophore 
requiring attachment of the substrate sequence in a non-
symmetric mode would be advantageous. Taking all this into 
consideration the two possible suitable synthetic strategies for 
this fluorophore substitution are: 
 
(i) Using a Singapore Green (SG) analogue (figure 47) this compound 
structurally allows attachment on to a single amino moiety, thereby 
fulfilling the requirement of non-symmetric functionalisation. The 
dye is reported to have a higher quantum yield and extinction 
coefficient like rhodamines in comparison to coumarin dyes as 
shown in table 19. SG is of particular interest as recently it has 
been demonstrated by Bywaters et al. as a dye that can be used for 
protease based detection systems.143 
NH O OR
 
Figure 47 – Structural representation of Singapore Green – R = alkyl  
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   Fluorophore ε (M-1cm-1) φ 
AMC 1.7x104 0.63 
Rhod 110 6.8x104 0.98 
Singapore Green 4.6x104 0.65 
Table 19 – List of fluorophore and their quantum yields and extinction 
coefficient values.143, 144 
 
(ii) Synthesising a novel fluorophore and incorporating the tripeptide 
functionalisation to a simple framework, a possible synthetic plan is 
attached of a hybrid of rhodamine b and R-110.145 
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Scheme 7 – Synthetic plan for rhodamine b/ R-110 hybrid conjugated to 
tripeptide analogue. 
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4.1.  GENERAL PROCEDURES AND INSTRUMENTATION. 
NMR was recorded using Brüker Avance III 400 two channel FT-NMR 
spectrometer and the Brüker Avance III 600 three channel FT-NMR 
spectrometer.
 1
H NMR spectra were recorded at either 400 or 600 MHz and 
13
C NMR spectra were recorded at 100 MHz. 
19
F NMR spectra were recorded 
at 376 MHz. Chemical shifts were referenced to the solvent used and noted in 
the experimental. IR (infrared) was recorded using Perkin Elmer Spectrum 
100 FT-IR spectrometer. GC/MS was recorded on Agilent Technologies 5973 
mass selective detector, 6890 N Network GC system. HRMS and elemental 
analysis results were obtained via Medac Ltd.  
TLC analysis was carried out on silica, aluminium oxide, reverse phase silica 
coated plates and were visualised by a single method or a combination of the 
following methods: (a) viewing under UV at 254 nm; (b) viewing under UV at 
365 nm; (c) exposure to a ninhydrin solution, containing 2g of ninhydrin in 
60mL of ethanol; (d) exposure to a vanillin solution, containing 6g of vanillin, 
250 mL of ethanol and 1.5 mL of 12M aqueous sulphuric acid.  
Preparative TLC was carried out on normal phase silica based plates; the 
mobile phase solvent mix is described in ratios in the procedure details. 
Manual columns were run using normal phase silica of particle size 250-500 
µm, 35-60 mesh.  
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4.2.  EXPERIMENTAL PROCEDURE 
4.2.1.  Synthesis of fragment 1 
4.2.1.1.  Synthesis of BocNHAla-LysOMe (62) 
HATU dipeptide coupling, product = BocAla-Lys(Z)OMe 
 
 
O
NH
O
O
NH
NH
O
O
O
O
 
 
62 
 
Under a nitrogen atmosphere, BocAlaOH (2.5g, 1.5eq, 13.2mmol), 
Lys(Z)OMe.HCl (2.91g, 1eq, 8.8mmol), HATU (6.69g, 2eq, 17.6mmol) were 
dissolved in 33 mL of anhydrous DMF. To this solution the base 
diisopropylethylamine (5.68g, 7.6mL, 5eq.) was added. The resultant yellow 
solution was left at 50°C overnight. Reaction progression was monitored via 
TLC. The reaction was quenched with 55mL of water and extracted with 
3x50mL ethyl acetate and further washed 3x40mL with saturated lithium 
chloride solution and dried over Na2SO4. Reaction mixture was concentrated 
under reduced pressure and placed on the high vacuum. The crude mixture 
was purified using the biotage autocolumn on silica with solvent conditions: 
2%MeOH:CHCl3to give BocAla-Lys(Z)OMe as a yellow oil (0.55g, 13%).1H 
NMR (400 MHz, chloroform-d)  1.32 (d, 3H), 1.37 (m, 2H), 1.43 (s, 9H), 1.53 
(m, 2H), 1.68 (m, 1H), 1.87 (m, 1H), 3.17 (m, 2H), 3.73 (s, 3H), 4.59 (m, 1H), 
5.01 (br.s, 2H), 5.10 (br.s, 1H), 6.73 (br.s, 1H, NH), 7.29-7.34 (m, 5H).13C 
NMR (400 MHz, chloroform-d) 172.6, 172.5, 156.5, 136.5, 128.5, 128.2, 
128.1, 77 (reference peak), 66.7, 60.4, 52.4, 40.4, 31.8, 29.1, 28.3, 22.0, 21.1, 
14.2, 10.0  Mass confirmed by GC/MS, as found 500 C23H30N3O7K, requires 
465 for C23H35N3O7. 
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4.2.1.2.  Synthesis of BocNHAla-Lys(Z)OH (63) 
 
O
NH
O
O
NH
NH
O
OH
O
O
 
63 
 
Under a nitrogen atmosphere, to a solution of BocAla-Lys(Z)OMe (0.55g, 
1.18mmol)  in THF:H2O (1:1) (10mL) was added LiOH.H2O (0.097g, 2.232 
mmol), the reaction mixture was left to stir at ambient temperature over two 
nights. Reaction progression monitored via TLC. The mixture was acidified 
using 5% aqueous HCl and extracted with ethyl acetate (15mL x 2) and 
washed with water (10mL x 1) then brine (10mL x1) and dried over Na2SO4. 
Reaction mixture was concentrated under reduced pressure and placed on 
the high vacuum. The crude mixture was purified using the biotage auto-
column on silica with solvent conditions 10 % MeOH: CHCl3 to afford a 
yellowy oil (0.19g, 35%).1H NMR (400 MHz, chloroform-d)  1.26 (d, 1H), 1.33 
(m, 2H), 1.42 (s, 9H), 1.51 (m, 2H), 1.76 (m, 1H), 1.91 (m, 1H), 3.17 (m, 2H), 
4.54 (m, 1H), 5.08 (br.s, 2H), 5.15 (br.s, 1H), 6.73 (br.s, 1H, NH), 7.36-7.38 
(m, 5H).13C NMR (400 MHz, chloroform-d) 172.6, 172.1, 156.4, 136.1, 127.9, 
128.1, 128.0, 77 (reference peak), 66.1, 60.0, 40.1, 31.5, 28.8, 28.1, 22.0, 
21.0, 14.1, 1.0. Mass confirmed by GC/MS, as found 490 C22H33N3O7K, 
requires 451 for C23H35N3O7. 
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4.2.1.3.  Synthesis of triflates 
 
O
S
O
O
F
F
F
 
64 
 
A solution of hydroxybenzene (0.5g, 2.3mmol) in DCM (30mL) was prepared 
and cooled to 0 °C. To this DIEA (0.47mL, 2.7mmol, 1.15eq.) and 
trifluoromethanesulfonic anhydride (0.44mL, 2.7mmol, 1.15eq.) were added 
and the reaction was stirred at room temperature for 1.5 hours. The reaction 
was quenched with water and extracted with DCM. The organic layer was 
washed with CuSO4(aq) and brine, dried over magnesium sulfate and filtered 
under gravity and concentrated under vacuum. The crude mixture was 
purified using flash chromatography on silica gel with mobile phase of hexane: 
ethylactetate of ratio 7:3 to afford a greeny-white crystalline solid (0.33g, 
61%). 1H NMR (400 MHz, chloroform-d) 7.39 (m, 2H), 7.32 (m, 1H), 7.2 (m, 
2H).13C NMR (100 MHz, chloroform-d) 149.33, 129.95, 128.07, 121.02, 53.8. 
19F NMR (376 MHz, chloroform-d) δ -72.7 (s); GC-MS found 226, requires 226 
for C7H5F3O3S. 
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A suspension of fluorescein (2.50g, 7.52mmol) in DCM (30mL) was prepared 
and cooled to 0 °C. To this pyridine (4.87mL, 60.2mmol, 8.0eq) and 
trifluoromethanesulfonic anhydride (5.06mL, 30.1mmol, 4.0eq) were added 
and the reaction was stirred a room temperature for 5 hours. The reaction was 
quenched with water and extracted with DCM. The organic layer was washed 
with CuSO4(aq) and brine, dried over magnesium sulfate and filtered under 
gravity  and concentrated under vacuum. The crude mixture was purified 
using flash chromatography on silica gel with mobile phase of hexane: 
ethylactetate of ratio 7:3 to afford a clear foam (47%).1H NMR (400 MHz, 
chloroform-d) 8.09 – 8.06 (m, 1H), 7.73 (td, J = 7.4, 1.4 Hz, 1H), 7.67 (td, J = 
7.4, 1.2 Hz,1H), 7.36 (d, J = 2.4 Hz, 2H), 7.27 – 7.15 (m, 1H), 7.03 (dd, J = 
8.8, 2.4 Hz, 2H), 6.93 (d, J = 8.8 Hz, 2H); 13C NMR(100 MHz, chloroform-d) 
166.16, 151.9, 151.2,150.5, 135.2, 129.1, 128.9, 124.5,125.1, 122.7, 120.3, 
119.8, 118.8, 111.3, 81.2. 19F NMR (376 MHz, chloroform-d)  
δ -72.9 (s); MS (ESI) found 404.2, requires 403.4 for C22H11F6O9S2. 
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4.2.2.  Synthesis of fragment 2. 
4.2.2.1.  Synthesis of 1-Azido-4-nitrobenzene-Azido-4-nitrobenzene 
 
N3 NO2
 
66 
 
pTsOH.H2O (1.71g, 9mmol, 9eq.) was dissolved in H2O (11mL). To this 
solution para nitro aniline (0.138g, 1mmol, 1eq.) was added. To the resulting 
suspension NaNO2 (0.76g, 18mmol, 9eq.) was slowly added over a period of 
10 minutes. The solution was left stirring at room temperature for an hour, 
then NaN3 (0.104g, 1.6mmol, 1.6eq) was added. The mixture was filtered 
under vacuum and washed with H2O (1 x 50mL), to afford a beige powder 
(0.15g, 92%). 1H NMR (400 MHz, DMSO-d6)  ppm 2.50 (solvent reference 
peak), 3.33 (H2O peak), 7.36 (s, 2H), 8.24 (s, 2H).13C NMR (100 MHz, 
DMSO-d6)  ppm 39.7 (solvent reference peak), 120.32, 125.78, 144.27, 
146.92. m.p 52.2-52.7°C, literature reference value 52°C.146 
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4.2.2.2.  Synthesis of BocGlnAMC – A four step process including 
deprotection-Azido 
 
Synthesis via selenocarboxylate/ azide amidation:1,2 
 
Part 1) 
O ON3
 
67 
 
pTsOH.H2O (3.42g, 18mmol, 9eq.) was dissolved in H2O (18mL). To this 
solution AMC (0.35g, 2mmol, 1eq.) was added. To the resulting suspension 
NaNO2 (1.52g, 18 mmol, 9eq.) was slowly added over a period of 10 minutes. 
The solution was left stirring at room temperature for an hour, then NaN3 
(0.21g, 3.2 mmol, 1.6eq.) was added. The mixture was filtered under vacuum 
and washed with H2O (1 x 50mL), to afford a beige powder (0.36g, 89%). 1H 
NMR (400 MHz, DMSO-d6)  ppm 2.41 (d, J=1.25 Hz, 3 H), 3.33 (H2O peak), 
6.34 (d, J=1.25 Hz, 1 H), 7.09 - 7.16 (m, 2 H), 7.77 (d, J=8.53 Hz, 1 H). 13C 
NMR (100 MHz, DMSO-d6)  ppm 17.87, 39.31 (solvent reference peak), 
106.59, 112.98, 115.35, 116.54, 126.78, 143.08, 152.73, 153.81, 159.32. m.p 
110.4-110.6°C, literature reference 110°C.147  
 
Part 2)  
Preparation of an isopropanol solution of sodium hydrogen selenide needed 
for part 3) 
 
To a suspension of degassed isopropanol (10mL) and selenium (93mg) was 
added sodium borohydride (53mg, 1.4mmol) and left stirring for 45 minutes to 
get a colourless solution ready for use.   
 
 
 
 
Chapter 4: Experimental 
 
 
 
 144 
Part 3)  
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NH2
O
 
68 
Under a nitrogen atmosphere, to a solution of BocGlnOH (0.29g, 1.18mmol, 
1.2eq.) and N –methyl piperidine (143µL, 1.18mmol, 1.2eq.) in DMF (5mL) 
was added isopropylchloroformate (162µL, 1.18mmol, 1.2eq.) at -15°C, the 
mixture was stirred at -15°C for a further 20 mins. The NaHSe solution 
prepared in part 2, was added to the mixed anhydride solution via cannulation 
slowly over a period of 5 mins. The reaction mixture was left for a further 30 
mins stirring below 10°C, and then a solution of the azide was prepared, azido 
methyl coumarin (0.2g, 0.98mmol, 1eq.) in DMF (4mL) and cannulated into 
the reaction mixture. The reaction was left stirring overnight at room 
temperature. Reaction progression confirmed via TLC. The volatile solvents 
were removed under pressure, redissolved in 30mL of DCM and washed with 
NaHCO3 (2 x 10mL), water (1 x 9mL) then brine (2 x 9mL) and dried over 
Na2SO4. Reaction mixture was concentrated under reduced pressure and 
placed on the high vacuum. The crude product was purified using prep TLC 
(3% MeOH:DCM) to give a white powder (0.0322g, 8%). 1H NMR (400 MHz, 
methanol-d4)  ppm 1.41 (s, 9 H), 1.94 (m, 1 H), 2.11 (m, 1 H), 2.37 (t, 2 H), 
2.45 (s, 3 H), 4.21 (m, 1 H), 6.23 (s, 1H), 7.5 (d, 1H), 7.7 (d, 1H) and 7.81 (d, 
1H). Grease peaks omitted. 13C NMR (100 MHz, DMSO-d6) ppm 18.46, 
28.63, 29.00, 32.39, 48.84 (solvent reference peak) 56.31, 80.72, 108.03, 
113.55, 117.13, 126.66, 130.65, 143.35, 155.2, 155.32, 163.18, 177.64.  
IR (ATR) vmax / cm-1 3370, 2976, 2928, 2409, 1640, 1613. TOF MS ES found 
404.2, requires 403.4 for C20H25N3O6. 
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Part 4) 
Boc deprotection to give NH2GlnAMC, 69 
 
O
O
NH
O
NH2
NH2
O
 
69 
 
The boc protected amino acid (0.0322g, 0.11mmol) was dissolved in DCM 
(1mL) to this solution TFA (0.2mL) was added and left to stir at room 
temperature for 1 hour. Reaction completion was detected via TLC. The 
volatile solvents were removed under reduced pressure, diluted with ethyl 
acetate, neutralised using NaHCO3 and dried over MgSO4. Reaction mixture 
was concentrated under reduced pressure and placed on the high vacuum. 
Product afforded as a yellowy smear in flask (0.029g, 87%). TLC used to 
determine reaction completion no further data was collected.1H NMR (400 
MHz, methanol-d4)  ppm (grease), 2.19 (m, 1 H), 2.35 (m, 1 H), 2.45 (s, 3H), 
2.53 (m, 2H), 4.35 (dd, 2H), 6.35 (s, 1H), 7.52 (dd, 1H), 7.70 (d, 1H), 7.81 
(d,1H). 13 C NMR (100 MHz, methanol-d4)  ppm 18.66, 26.99, 30.63, 49.15 
(solvent reference peak), 58.99, 108.26, 113.90, 117.31, 126.93, 131.49, 
143.45, 155.34, 155.50, 163.29, 173.62, 181.74. 
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4.2.2.3.  Final peptide coupling to give BocAlaLys(Z)GlnAMC, 70. 
 
O
NH
ONH
NH
O
O
O
O
O
O
NH
O
NH
NH2
O
 
70 
 
Under a nitrogen atmosphere, BocAlaLys(Z)OH (65mg, 0.14mmol, 1.5eq.), 
NH2GlnAMC (29mg, 0.96mmol, 1eq.), HATU (72 mg, 0.19 mmol, 2eq.) were 
dissolved in 1.5ml of anhydrous DMF. To this solution the base) was added 
DIEA (5.68g, 80µL, 5eq.). The resultant yellow solution was left at 50°C for a 
week. Reaction progression was monitored via TLC. The reaction was 
quenched with 2mL of water and extracted with 6 mL ethyl acetate and further 
washed 3 x 2mL with saturated lithium chloride solution and dried over 
Na2SO4. Reaction mixture was concentrated under reduced pressure and 
placed on the high vacuum. The crude mixture was purified using preparative 
TLC (6.5% MeOH:DCM) (3mg, 0.4%),1H NMR (400 MHz, methanol-d4)  ppm 
1.26 - 1.35 (m, 1 H), 1.41 - 1.46 (m, 9 H), 1.47 - 1.51 (m, 1 H), 1.51 - 1.52 (m, 
1 H), 1.52 - 1.54 (m, 1 H), 1.88 - 1.90 (m, 1 H), 2.43 - 2.48 (m, 1 H), 2.69 - 
2.73 (m, 1 H), 2.91 - 2.93 (m, 1 H), 3.09 - 3.16 (m, 1 H), 3.34 - 3.36 (m, 1 H), 
3.45 - 3.50 (m, 1 H), 3.62 - 3.65 (m, 1 H), 5.02 - 5.07 (m, 1 H), 6.21 - 6.26 (m, 
1 H), 7.25 - 7.38 (m, 1 H), 7.67 - 7.76 (m, 3 H), 7.85 - 7.87 (m, 1 H), 7.90 - 
7.95 (m, 1 H). ES TOF MS found 737.35, requires 736.8 for C37H48N6O10. 
Molecular formula verified by elemental analysis: C, 60.01; H,6.87; N, 11.37; 
O, 21.70. 
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4.2.2.4.  Final peptide coupling to give BocAlaLys(Boc)Gln(Trt)AMC, 71. 
 
HATU coupling of tripeptide sequence to the AMC to synthesise 
BocAlaLys(Boc)Gln(Trt)AMC, 71 
O
NH
ONH
NH
O
O
O
O
O
O
NH
O
NH
NH
O
 
71 
  
Under a nitrogen atmosphere, BocAlaLys(Boc)Gln(Trt)OH (50 mg, 
0.0634mmol, 1eq.), AMC (11 mg, 0.0635 mmol, 1eq.), HATU (48 mg,  
0.127mmol, 2eq.) were dissolved in 5ml of anhydrous DMF. To this solution 
the base DIEA (41 mg, 55µL, 5 eq.) was added. The resultant yellow solution 
was left at 50°C for 3 nights. Reaction progression was monitored via TLC. 
The reaction was quenched with 10mL of water and extracted with 3 x 10mL 
ethyl acetate and further washed 3 x 8mL with saturated lithium chloride 
solution and dried over Na2SO4. Reaction mixture was concentrated under 
reduced pressure and placed on the high vacuum. The crude mixture was 
purified using the preparative TLC with solvent conditions: 5%MeOH:DCM to 
give BocAlaLys(Boc)Gln(Trt)AMC as a clear oil (10 mg, 15.7%). 1H NMR (400 
MHz, methanol-d4)  ppm 1.05 - 1.22 (m, 3 H) 1.23 - 1.35 (m, 4 H) 1.37 - 1.53 
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(m, 18 H) 2.81 (s, 1 H) 2.86 (d, J=0.75 Hz, 1 H) 2.96 - 3.08 (m, 2 H) 3.69 (d, 
J=6.78 Hz, 1 H) 3.81 - 4.17 (m, 1 H) 4.34 - 4.51 (m, 1 H) 4.58 - 4.67 (m, 1 H) 
4.68 - 4.80 (m, 1 H) 6.22 - 6.25 (m, 1 H) 7.13 - 7.33 (m, 15 H). 13 C NMR (100 
MHz, methanol-d4)  ppm,16.61, 17.31, 18.43, 19.91, 23.10, 27.45, 28.12, 
28.41, 29.93, 30.35, 30.83, 31.31, 32.6, 33.24, 33.33, 36.46, 37.10, 38.35, 
40.23, 49.05, 49.20, 51.56, 54.27, 111.13, 117.25, 121.35, 122.05, 127.04, 
128.18, 128.21, 133.5. Mass confirmed by TOF MS ES as found 967.4595 
C53H64N6O10Na, requires 945 for C53H64N6O10, Molecular formula verified by 
elemental analysis: C, 67.31; H, 6.87; N, 8.81; O, 16.70. 
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